CN105777632A - Aromatic-ring azacyclo derivatives and application thereof - Google Patents

Aromatic-ring azacyclo derivatives and application thereof Download PDF

Info

Publication number
CN105777632A
CN105777632A CN201610009779.2A CN201610009779A CN105777632A CN 105777632 A CN105777632 A CN 105777632A CN 201610009779 A CN201610009779 A CN 201610009779A CN 105777632 A CN105777632 A CN 105777632A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
heteroaryl
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610009779.2A
Other languages
Chinese (zh)
Inventor
李德群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Beisi Kairui Biological Technology Co Ltd
Original Assignee
Chengdu Beisi Kairui Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Beisi Kairui Biological Technology Co Ltd filed Critical Chengdu Beisi Kairui Biological Technology Co Ltd
Publication of CN105777632A publication Critical patent/CN105777632A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aromatic-ring azacyclo derivatives and an application thereof are provided. The invention relates to compounds represented by the formula (V), and a preparation method and an application thereof in medicines. In particular, the invention relates to derivatives of the compounds represented by the general formula (V), and a preparation method and the application thereof as therapeutic agents in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compounds disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, increase the expression of hepatic LDL receptors and inhibit the expression of PCSK9.

Description

Aromatic ring azacyclo-derivant and application thereof
Technical field
The technology of the present invention relates to treatment hyperlipemia (including hypertriglyceridemia and hypercholesterolemia), fatty degeneration of liver, type ii diabetes, hyperglycemia, insulin resistance, obesity, Metabolic syndrome is sought peace cancer purposes, compound and compositions.
Background technology
Metabolism syndrome (MetabolicSyndrome, MS) is the pathological state of multiple Metabolite abnormal aggregation, is a complex set of metabolism disorder disease group, is cause diabetes, the risk factor of cardiovascular and cerebrovascular disease.
Cardiovascular and cerebrovascular disease is the number one killer of harm human health, its cause of disease is extremely complex, hyperlipidemia receives again the concern of most people as its very crucial risk factor, and along with the acceleration of the improvement of living standard and aging, the incidence rate of hyperlipidemia and mortality rate are obviously improved, more having pertinent literature to report, dyslipidemia is the main cause causing atherosclerosis, coronary heart disease, myocardial infarction etc..
Hyperlipidemia is often interpreted: the metabolism of fat or operating make one or more lipids in blood plasma be higher than normal extremely.And hyperlipidemia is the disease of kind of general, being often referred in serum T-CHOL (TC), triglyceride (TG) is too high or HDL-C (HDL-C) is too low, and modern medicine is referred to as dyslipidemia.Lipid is to be insoluble or poorly soluble in water, so lipoprotein must be formed with protein bound, therefore, hyperlipidemia is also commonly referred to as hyperlipoproteinemia.
Hyperlipidemia and cerebral infarction: Blood Cholesterol increases and easily forms arteriosclerosis plaque, when these specklees are piled up in arterial wall, can make tremulous pulse official jargon narrow, blocks blood and flows into corresponding position, will cause kinetic energy defect.When it occurs to cause cerebral infarction when cerebrovascular, medical evidence: long-term Lipid modulating can not only treat cerebral infarction, moreover it is possible to prevention cerebral infarction.
Hyperlipidemia and coronary heart disease: coronary heart disease is also called coronary atherosclerotic heart disease.Coronary artery is to the major arteries of heart blood supply, if excess fat deposition, will cause arteriosclerosis, so that blood flow is obstructed, cause heart ischemia, a series of symptom occur, i.e. coronary heart disease.The risk factor causing coronary heart disease is a lot, such as hyperlipidemia, smoking, obesity, hypertension, shortage physical exertion, diabetes, familial history of coronary artery disease etc., wherein, hyperlipidemia be again one of important risk factor causing coronary heart disease.So preventing and treating the most basic therapy of coronary heart disease is regulate blood fat, research shows that in serum, total cholesterol level declines 1%, then coronary heart disease incidence rate declines 2%.The long-term incidence rate and the mortality rate that coordinate Lipid modulating can reduce the angina pectoris of coronary heart disease, myocardial infarction etc..
Hyperlipidemia and fatty liver: fatty liver refers to that fat caused by a large amount of accumulation, often increases with blood fat in liver.Pathogenesis of fatty liver rate is up to 5-10%, and in adult body, Cyklokapren increased perosn about 35% is fatty liver, and part severe patient can develop into liver cirrhosis.Therefore, fatty liver treatment also should carry out adjusting the treatment of fat.
Hyperlipidemia and diabetes: hypertension, hyperlipidemia and hyperglycemia are commonly referred to as " three high ", be the principal element threatening diabetics healthy.Three is closely related, hyperlipidemia can increase the weight of the symptom of diabetes, most of diabeticss are with hyperlipidemia, more it is easily caused apoplexy, coronary heart disease, limb necrosis, retinopathy, nephropathy, neuropathy etc., therefore diabetics is wiped out and treated insect pests and plant diseases outside treatment hyperglycemia, should also be noted that Adjust-blood lipid, this is extremely important for reducing diabetics mortality rate and disability rate.
Hyperlipidemia is defined as blood fat disorder or dyslipidemia.It is often referred to blood in human body in lipid concentration beyond normal range.Raising including triglyceride (TG), serum total cholesterol (TC), C-VLDL (VLDL-C) or low-density lipoprotein cholesterol (LDL-C) level and HDL-C (HDL-C) level reduces along with the further investigation of hyperlipidemia Yu cardiovascular disease, people start to recognize that the risk reducing cardiovascular disease is had very important significance by blood fat reducing.
Blood lipid-lowering medicine conventional currently on the market mainly has Statins, fibrates, nicotinic acid class, cholic acid chelating agent class etc..
Statins represents medicine: atorvastatin, simvastatin, lovastatin, pravastatin, fluvastatin etc..This kind of medicine is development in recent years ratio fat-reducing medicament faster, is mainly the activity of rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase suppressed in serum total cholesterol (TC) route of synthesis, reduces TC synthesis；Low density lipoprotein receptor quantity is increased, accelerates LDL degraded, increase HDL content simultaneously, be conducive to removing and the transhipment of TC.
Weak point: its side effect brought is inevitable, as: rhabdomyolysis, the various enzymatic activity enhancings etc. of myositis and liver, some patients are additionally had to fail to well adapt to the treatment of statins, it is often more important that single Statins treatment also tends to reach intended ideal effect.
Fibrates represents medicine: clofibrate, gemfibrozil, FENOBRATE top grade.Such medicine is through long-term clinical practice, the medicine of the Regulation serum lipids have proven to a class better tolerance, having had.Its blood fat reducing approach also has the activity increasing lipoprotein lipase except similar with Statins, makes the removing of triglyceride (TG) increase；Reduce blood glucose, so that second coenzyme A and free fatty trend towards the synthesis of glucose, make lipid synthesis reduce.
Weak point: untoward reaction often occurs in digestive tract, there is anaphylaxis in occasional, and visual disorder, owing to such medicine adds cholesterol concentration in bile, so being also possible to cause cholelithiasis.
Nicotinic acid class represents medicine: nicotinic acid, inositol niacinate, acipimox etc..The formation of this kind of medicine decomposition and free fatty mainly through suppressing fat, it is suppressed that liver synthetic glycerine three ester (TG) and very low density lipoprotein (VLDL) (VLD-L) reduce blood fat.
Weak point: diabetics effect for reducing blood fat is inconspicuous, side effect such as liver poisoning, the untoward reaction such as hyperglycemia is comparatively obvious, skin epidemic disease often occurs, pruritus.
Cholic acid chelating agent class represents medicine: Ezetimibe (Ezetimibe), how rare unsaturated fatty acid etc..This kind of fat-reducing medicament can be divided into cholesterol absorption inhibitor and how rare unsaturated fatty acid two class.
(1), cholesterol absorption inhibitor (Ezetimibe): be combined with bile acid, hinder the heavily absorption of bile acid, thus promoting cholesterol to be converted into bile acid, combining at intestinal and this medicine and excreting.
(2), polyene unsaturated fatty acid: be combined into esters with cholesterol, promote cholesterol degradation be bile acid with bile excretion so that the concentration of blood bavin T-CHOL reduces.
Low density lipoprotein, LDL (LDL) level crosses high energy atherogenicity, reduces plasma LDL levels and prevention and treatment cardio-cerebrovascular diseases are had great importance.In blood, the LDL of about 70% is that the endocytosis mediated by low density lipoprotein receptor (LDLR) completes to remove, the expression of LDLR is subject to the impact of proprotein convertase subtilisin/kexin9 type (proproteinconvertasesubtilisin/kexintype9) (PCSK9), PCSK9 is a serine protease, main in liver synthesis, it can reduce LDLR quantity in hepatocyte.After PCSK9 and the LDLR being positioned at cell surface is combined, internalization, to cell, promotes LDLR degraded in lysosome.The activity suppressing PCSK9 can increase LDLR quantity, reduces LDL level in blood plasma.
The exploitation of PCSK9 inhibitor is the important directions that current large-scale transnational drugmaker makes great efforts research and development Novel cardiovascular disease medicament, expects that this kind of medicine surmounts the fat-reducing medicament that Statins is ripe.Big drug firm promotes PCSK9 inhibitor medicaments development just underway, current research work is concentrated mainly on the exploitation (such as following table) of biological medicine (including protein drug and long nucleic acid medicine), biological medicine and small-molecule drug are for when treating same disease, biological medicament has with high costs, the shortcomings such as limited preparation way such as ejection preparation can only be adopted, at present, clinical candidates is become but without little molecule PCSK9 inhibitor.
Disclose the micromolecular compound patent application of a series of PCSK9 inhibitor at present, including WO2010075469, WO2011006000, WO2011051961, WO2011152508, WO2012090220, JP2013136572, WO2013132509, WO2013137371, WO2014017569, WO2014002105, WO2014002106, WO2014150326, WO2014150395, WO2014139008 etc..
Although having been disclosed for a series of compound having and suppressing PCSK9 expression and lipid-lowering effect at present, but, need nonetheless remain for that exploitation is new has better drug effect, medicine is for the compound of result, through being continually striving to, present invention design has a compound of logical formula V structure and discovery has the compound of this class formation and shows effect and the effect of excellence, in a wider context, more deeply and all sidedly disclose and illustrate structure and the relation of activity usefulness, there is important using value.
Summary of the invention
It is an object of the invention to provide compound shown in a kind of logical formula V and their tautomer, enantiomer, diastereomer, raceme and pharmaceutically useful salt, and metabolite and metabolic precursor thereof or prodrug.The compound of Formula V
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof；Wherein:
Annular atoms A or E is each independently selected from carbon atom or nitrogen-atoms；
A and E is connected with each other and is connected into 3～10 ring Y, meets valence bond theory during cyclization, and 3～10 described ring Y are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R1, R2, R3, R4, R5, R6Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
Z is-O-,-S-,-NH-,-CR5R6-,-C (O) O-,-C (O) NH-,-SO2O-,-SO2NH-, or Z is not for any atom (two groups namely, being connected with Z are connected either directly through chemical bond)；
Ring X is 3～10 rings, and 3～10 described ring X are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R ' and R " independent is hydrogen or be substituted or the alkyl that is unsubstituted, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl,
At-NR ' R " ,-C (O) NR ' R " ,-OC (O) NR ' R " and ,-OS (O)nNR ' R " ,-OS (O)nNH (C=O) NR ' R " in, wherein NR ' R " can be 4 to 20 member heterocyclic ring containing nitrogen bases；
M=0,1,2；
N=1,2,3；
P=1,2,3；
Q=0,1,2,3,4,5,6；
R=0,1；
S=0,1,2.
The present invention relates to general formula compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VI),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
Annular atoms A or E is each independently selected from carbon or nitrogen-atoms；
A and E is connected with each other and is connected into 3～10 ring Y, meets valence bond theory during cyclization, and 3～10 described ring Y are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R9, R10, R11, R12, R13, R14Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R5, R6, R ', R ", Z, ring X, m, n, q, r are with described previously.
The present invention relates to general formula compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R9, R10, R11, R12, R13, R14Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R15, R16, R17, R18It is hydrogen independently, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R5, R6, R ', R ", Z, annular atoms A, ring X, m, n, q, r are with described previously.
The present invention relates to general formula compound (VII), wherein, R9, R10, R11, R12, R13, R14It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R15, R16, R17, R18It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
The present invention relates to general formula compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VIII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R19, R20, R21, R22, R23It is hydrogen independently, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
Annular atoms A and E, ring Y, R1, R2, R3, R4, R5, R6, R ', R ", Z, m, n, p, q, r, s is with described previously.
The present invention relates to general formula compound (VIII), wherein, R19, R20, R21, R22, R23It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
The present invention relates to general formula compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (IX),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R9, R10, R11, R12, R13, R14, R15, R16, R17, R18With described previously；
R19, R20, R21, R22, R23With described previously；
R5, R6, annular atoms A, q, r are with described previously.
The present invention relates to general formula compound (IX), wherein: R15, R16, R17, R18, R19, R20, R21, R22, R23It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
The present invention relates to compound shown in logical formula V, this compound is selected from following compound, but is not limited to following compound range:
Or its medicinal acceptable salt.
The present invention relates in compound shown in logical formula V the compound described in any one in preparation for treating type ii diabetes, hyperglycemia, the purposes in the medicine of obesity or insulin resistance.
The present invention relates to compound shown in logical formula V, its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof, it comprises the following steps:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compound V by connecting.
The present invention relates to compound shown in logical formula V, a kind of pharmaceutical composition of preparation, its compound comprising any one and pharmaceutically acceptable carrier.
The present invention relates to a kind of pharmaceutical composition of the composition of compound shown in logical formula V, described compositions includes the compound giving any one of the effective therapeutic dose of patient of needs treatment.
The present invention relates to any one compound purposes in the medicine of the lipid levels prepared for reducing patients blood plasma and/or liver in compound shown in logical formula V.
The present invention relates in compound shown in logical formula V any one compound in preparation for treating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, the purposes in disease that fatty degeneration of liver and metabolism syndrome are constituted or the medicine of the patient's condition.
The present invention relates to any one compound in compound shown in logical formula V and express and/or reduce the purposes in the PCSK9 medicine expressed in preparation for increasing LDLR.
The present invention relates to any one compound purposes in preparing the medicine for reducing LDL-cholesterol and/or plasma triglyceride in compound shown in logical formula V.
The present invention relates in compound shown in logical formula V the compound described in any one in preparation for treating type ii diabetes, hyperglycemia, obesity, insulin resistance and the purposes in antitumor drug.
The present invention relates to compound shown in logical formula V, compound disclosed by the invention has the advantages that
1, disclosed by the invention have logical formula V micromolecular compound, is suppressing PCSK9 gene expression, is increasing the expression of cell LDLR, strengthens hepatocyte to the remarkable effect in the picked-up ability of LDL, is expected to become a new generation's lipid lowerers.
PCSK9 inhibitor is the important directions that current large-scale transnational drugmaker makes great efforts research and development Novel cardiovascular disease medicament as the exploitation of fat-reducing medicament, expects that this kind of medicine surmounts the fat-reducing medicament that Statins is ripe.Big drug firm promotes PCSK9 inhibitor medicaments development just underway, current research work is concentrated mainly on the exploitation of biological medicine (including protein drug and long nucleic acid medicine), at present, clinical candidates is become but without little molecule PCSK9 inhibitor.
Biological medicine and small-molecule drug are for when treating same disease, biological medicament has with high costs, the shortcomings such as limited preparation way such as ejection preparation can only be adopted, and small-molecule drug has cheap for manufacturing cost, the advantages such as formulation method is various, disclosed by the invention have logical formula V micromolecular compound, shows significant suppression PCSK9 gene expression at cellular level, strengthen hepatocyte to the remarkable effect in the picked-up ability of LDL, be expected to become there is lipid lowerers of new generation.On the other hand, the formulation protocol of small-molecule drug selects face more extensive than biopharmaceutical macromolecular drug, is conducive to the exploitation of the multiple drug form of later stage drug development, compares biopharmaceutical macromolecular drug, can be supplied to as preparation type widely, meet the demand of people.
2, with existing patent documentation disclosed in the PCSK9 Compound Phase ratio of target spot for effect, disclosed by the invention have logical formula V compound, novel structure, it is expected to become the drug candidate that PCSK9 is had the novel mechanism of action, and eventually becomes a new generation there is the fat-reducing medicament of novel mechanism of action.
Existing patent document reports a few class and acts on the micromolecular compound of PCSK9 target spot, is summarized as follows with patent applicant's classification:
A, CVIPharmaceuticalLimited apply for a patent WO2010075469, WO2011006000 reports the micromolecular compound obtained based on natural product corydaline structure of modification, such is based on the micromolecular compound of Structures of Natural Products, its manufacturing process is complicated, partial synthesis method needs to use the chemical reagent of severe toxicity, brings bigger harm can to operator and natural environment.
B, CadialaHealthcareLimited apply for a patent WO2011051961, WO2012090220, WO2013132509, WO2014002105, reporting a few micromolecular compound in WO2014002106, these a few micromolecular compounds mainly contain a common chemical constitution fragment hexahydro pyrans methylamino structure fragment in molecular structure feature.This structure fragment is likely to play important role in compound structure with biological activity.
C, KowaCompanyLimited apply for a patent WO2011152508, JP2013136572, WO2013137371, WO2014017569 reports a few micromolecular compound, this kind of micromolecular compound molecular structure relative complex, general embodiment compound is possibly together with three chiral centres, and its manufacture difficulty is relatively large, and embodiment compound is it is generally required to six step chemical reactions (not including the structure of the structure fragment containing chiral centre) just can prepare target compound.
nulld、AmorchemHoldingsINC. apply for a patent in WO2014139008 and report small molecule compound，The section Example compound main structure of such micromolecular compound is in that containing " borate and boric acid " structure fragment，Although having listed multiple myeloma medicine bortezomib (containing " boric acid " structure fragment) at present，But " boric acid class " medicine is at non-therapeutic field of tumor (such as: diabetes，Hyperlipemia etc.) application nevertheless suffer from restriction，Main reason is that the potential neurotoxic side effects of boracic medicine，And its potential chemical characteristic (Chem.Res.Toxicol. with living organism " irreversible fixation ",2013,26(4),pp608–615)，Potential " carcinogenecity " being likely to result in SARS drug design of this chemical characteristic，" genotoxicity " has extensively been subject to the attention of Pharmaceutical Chemist.
E, ShifaBiomedicalCorporation apply for a patent WO2014150326, WO2014150395 reports two micromolecular compounds, the preparation method relative complex of these micromolecular compounds, the preparation of the compound that some expression activitiy is outstanding needs to use heavy metal catalyst reaction, and uses isocyanate compound.
Summarized above is exactly with the PCSK9 micromolecular compound being action target spot in current disclosed document.Compound disclosed by the invention is equally with PCSK9 for action target spot, and this compounds is all likely to become the newtype drug of following Based PC SK9 action target spot with a few micromolecular compounds of above-mentioned summary.
With existing patent documentation disclosed in the PCSK9 Compound Phase ratio of target spot for effect, disclosed by the invention have logical formula V compound, novel structure, there is brand-new unique structural feature, imply that the molecular structure feature of its novelty of compound disclosed by the invention, likely bring unexpected " quasi-medicated property feature ", be expected to become the drug candidate that PCSK9 is had the novel mechanism of action, and eventually become a new generation there is the fat-reducing medicament of novel mechanism of action.
3, disclosed by the invention have logical formula V compound, has raw material and is easy to get, and preparation process is simple to operate, advantage with low cost.
The micromolecular compound with logical formula V disclosed by the invention, the commercially available intermediate of main employing, then adopt simple chemical reaction to carry out fragment coupled reaction and prepare.Having " amine " for example with commercially available, " aldehyde ", " carboxylic acid halides ", the functional group such as " halogenated hydrocarbons " is starting material, namely can prepare target compound.Therefore, disclosed by the invention have logical formula V compound, has raw material and is easy to get, and preparation process is simple to operate, advantage with low cost.
4, disclosed by the invention have logical formula V compound have activation the kinase whose activity of AMPK, prompting the compounds of this invention not only can be developed into a new generation's lipid lowerers, and the effect better controlling blood glucose can be played, in blood fat reducing and blood sugar lowering, obtain the existing single drugs with function more advantage of comprehensive benefit ratio for vast Metabolic Syndrome Patients.
General formula compound disclosed by the invention (V) preparation is prepared essentially according to following scheme:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound V by connecting.
Now for synthetically prepared flow process representative in patent of the present invention, introducing general formula compound (V) and prepare scheme, the compounds of this invention is prepared scheme and is not limited to following representative flow process:
Representative flow process one: for the compound of r=0 in general formula compound (V):
Scheme 1:
X1 and X3 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X3 under certain reaction condition, under certain alkaline reagent existent condition, prepare V-1 by nucleophilic substitution.
Scheme 2:
X1 and X4 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X4 under certain reaction condition, prepare V-1 by the reaction of reduction amination.
Representative flow process two: for the compound of r=1 in general formula compound (V):
Scheme 3:
X1 and X5 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X5 under certain reaction condition, under certain alkaline reagent existent condition, prepare V-2 by coupled reaction.
Further, formula (VI):
Y1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VI by connecting.
Further, formula (VII):
K1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.K1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VII by connecting.
Further, formula (VIII):
X1 and L1 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and L1 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VIII by connecting.
Further, formula (IX):
K1 and Z1 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.K1 and Z1 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound IX by connecting.
Now for synthetically prepared flow process representative in patent of the present invention, introducing general formula compound (VIII) and prepare scheme, the compounds of this invention is prepared scheme and is not limited to following representative flow process:
Representative flow process one: for the compound of r=0 in general formula compound (IX):
Scheme 1:
K1 and Z2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z2 under certain reaction condition, under certain alkaline reagent existent condition, prepare IX-1 by nucleophilic substitution.
Scheme 2:
K1 and Z3 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z3 under certain reaction condition, prepare IX-1 by the reaction of reduction amination.
Representative flow process two: for the compound of r=1 in general formula compound (VIII):
Scheme 3:
K1 and Z4 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z4 under certain reaction condition, under certain alkaline reagent existent condition, prepare IX-2 by coupled reaction.
Accompanying drawing illustrates:
After Fig. 1 shows compound treatment, the fluorescence intensity that basis of microscopic observation arrives is evaluated sample and hepatocyte is absorbed the impact of LDL ability.
Fig. 2 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of low-density lipoprotein cholesterol (LDL-C) compares.
Fig. 3 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of T-CHOL (TC) compares.
Fig. 4 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of glutamate pyruvate transaminase (ALT) compares.
Fig. 5 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of glutamic oxaloacetic transaminase, GOT (AST) compares.
Detailed Description Of The Invention
In many aspects, present technology provides the compound of novelty and the purposes that this compound is in reducing the purposes of lipid levels of blood plasma and/or liver and treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type ii diabetes, hyperglycemia, insulin resistance, obesity and metabolism syndrome.Compound provided herein can be formulated for the pharmaceutical composition in method disclosed herein and medicament.Present invention also offers described compound for preparing the purposes of pharmaceutical formulation and medicament, described compound purposes in the lipid levels reducing blood plasma and/or liver and described compound are in treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type ii diabetes, hyperglycemia, the purposes in insulin resistance, obesity and metabolism syndrome.
Following term is middle in the whole text herein to be used with reference to following definitions.
Generally, mention certain element, for instance hydrogen or H, represent all isotopes including this element.Such as, if R group is defined to include hydrogen or H, it also includes deuterium and tritium.Comprise radiosiotope (such as tritium, C14、P32And S35) compound therefore also in the scope of the present invention.For by this type of labelling insert the present invention compound in means be that those skilled in the art are apparent based on disclosure herein.
Generally, " being substituted " represents such organic group (such as alkyl) as defined below, and the key of the connected non-hydrogen atom of the key of the one or more connection hydrogen wherein contained or non-carbon is replaced.The group being substituted also includes such group: wherein one or more keys connecting carbon atom or hydrogen atom are replaced by the heteroatomic key of one or more connections (including double or triple bonds).Thus, unless otherwise, the group being replaced is replaced by one or more substituent groups.In some embodiments, substituent group is replaced by 1,2,3,4,5 or 6 substituent groups.(namely the example of substituent group includes halogen, F, Cl, Br and I), hydroxyl, alkoxyl, alkene oxygen base, aryloxy, aralkyl oxy, heterocyclyloxy and heterocyclylalkoxy, carbonyl, carboxyl, ester, carbaminate/ester, oxime, hydroxylamine, alkoxyamine, aralkoxy amine, sulfur alcohol, sulfide, sulfoxide, sulfone, sulfonyl, sulfonamide, amine, N-oxide, hydrazine, hydrazides, hydrazone, azide, amide, urea, amidine, guanidine, enamine, acid imide, isocyanates/ester, isothiocyanate/ester, cyanate/ester, thiocyanate/ester, imines, nitro, nitrile etc..
The ring base being substituted, for instance cycloalkyl, aryl, heterocyclic radical and the heteroaryl being substituted, also includes the ring and the loop systems that wherein connect the key replacement of the connected carbon atom of key of hydrogen atom.Cycloalkyl, aryl, heterocyclic radical and the heteroaryl being substituted also can by defined below that be substituted or that be unsubstituted alkyl, thiazolinyl and alkynyl substituted.
Alkyl includes the straight or branched group comprising 1 to 20 carbon atom, it is preferable that containing the alkyl of 1 to 12 carbon atom.nullLimiting examples includes methyl、Ethyl、N-pro-pyl、Isopropyl、Normal-butyl、Isobutyl group、The tert-butyl group、Sec-butyl、N-pentyl、1，1-dimethyl propyl、1，2-dimethyl propyl、2，2-dimethyl propyl、1-ethyl propyl、2-methyl butyl、3-methyl butyl、N-hexyl、1-Ethyl-2-Methyl propyl group、1，1，2-thmethylpropyl、1，1-dimethylbutyl、1，2-dimethylbutyl、2，2-dimethylbutyl、1，3-dimethylbutyl、2-ethyl-butyl、2-methyl amyl、3-methyl amyl、4-methyl amyl、2，3-dimethylbutyl、N-heptyl、2-methylhexyl、3-methylhexyl、4-methylhexyl、5-methylhexyl、2，3-dimethyl amyl group、2，4-dimethyl amyl group、2，2-dimethyl amyl group、3，3-dimethyl amyl group、2-ethyl pentyl group、3-ethyl pentyl group、N-octyl、2，3-dimethylhexanyl、2，4-dimethylhexanyl、2，5-dimethylhexanyl、2，2-dimethylhexanyl、3，3-dimethylhexanyl、4，4-dimethylhexanyl、2-ethylhexyl、3-ethylhexyl、4-ethylhexyl、2-methyl-2-ethyl pentyl group、2-methyl-3-ethyl pentyl group、N-nonyl、2-methyl-2-ethylhexyl、2-methyl-3-ethylhexyl、2，2-diethyl amyl group、Positive decyl、3，3-diethylhexyl、2，2-diethylhexyl，And various branched chain isomers etc..More preferably contain the low alkyl group of 1 to 6 carbon atom, non-limiting example includes methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, sec-butyl, n-pentyl, 1, 1-dimethyl propyl, 1, 2-dimethyl propyl, 2, 2-dimethyl propyl, 1-ethyl propyl, 2-methyl butyl, 3-methyl butyl, n-hexyl, 1-Ethyl-2-Methyl propyl group, 1, 1, 2-thmethylpropyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethyl-butyl, 2-methyl amyl, 3-methyl amyl, 4-methyl amyl, 2, 3-dimethylbutyl etc..Alkyl can be replace or non-substituted, when substituted, substituent group can be replaced on any spendable junction point, described substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, oxo ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Cycloalkyl-alkyl refers to the alkyl that the unsaturated monocycle of saturated or part or multi-ring cyclic hydrocarbon replace, and cycloalkyl ring comprises 3 to 20 carbon atoms, it is preferable that comprise 3 to 12 carbon atoms, more preferably comprises 3 to 10 carbon atoms.The limiting examples of monocyclic cycloalkyl includes cyclopropyl, cyclobutyl, cyclopenta, cyclopentenyl, cyclohexyl, cyclohexenyl group, cyclohexadienyl, suberyl, cycloheptatriene base, ring octyl group etc.；Polycyclic naphthene base includes the cycloalkyl of volution, condensed ring and bridged ring.
Thiazolinyl refers to by the unsaturated alkyl as defined above being at least made up of two carbon atoms and at least one carbon-to-carbon double bond, for instance vinyl, 1-acrylic, 2-acrylic, 1-, 2-or 3-cyclobutenyl etc..Thiazolinyl can be replace or non-substituted, when substituted, substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Cycloalkenyl group refers to include having at least one double bond being between two carbon atoms, unsaturated cycloalkyl as defined above.In some embodiments, cycloalkenyl group can have one, two or three double bonds but not including that aromatic compound.Cycloalkenyl group comprises 4 to 14 carbon atoms, or in some embodiments, comprises 5 to 14 carbon atoms, it is preferable that comprise 5 to 10 carbon atoms, more preferably comprises 5,6,7 or 8 carbon atoms.The example of cycloalkenyl group includes cyclohexenyl group, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl and hexadienyl.
Alkynyl refers to the unsaturated alkyl as defined above being at least made up of two carbon atoms and at least one carbon-to-carbon triple bond, for instance acetenyl, 1-propinyl, 2-propynyl, 1-, 2-or 3-butynyl etc..Alkynyl can be replace or non-substituted, when substituted, substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Aryl is free from heteroatomic cyclic aromatic hydrocarbon.Aryl includes monocycle, bicyclo-and three-loop system in this article.Therefore, aryl includes but not limited to phenyl, azulene cyclopentacycloheptene base, diphenyl, fluorenyl, phenanthryl, anthryl, indenyl, indanyl, pentalene base and naphthyl.In some embodiments, aryl contains 6-14 carbon in the part of the ring of group, it is preferable that 6 to 12, more preferably 6-10 carbon atom.In some embodiments, aryl is phenyl or naphthyl.Although phrase " aryl " includes the group (such as indanyl, tetralyl etc.) containing the ring (the aromatic-aliphatic loop systems such as condensed) condensed, but its aryl not including there is other group (such as alkyl or halo group) being bonded with one of ring members.The groups such as tolyl are referred to as the aryl being substituted.The representational aryl being substituted can through mono-substituted or be replaced and exceed once.Such as, including but not limited to, through mono-substituted aryl, the phenyl or naphthyl that 2-, 3-, 4-, 5-or 6-replace, it can be replaced by such as substituent group listed above.
The alkyl that aralkyl is as defined above, wherein, the hydrogen of alkyl or carbon bond are connected the key of aryl defined above and are replaced.In some embodiments, aralkyl contains 7 to 16 carbon atoms, it is preferable that 7 to 14 carbon atoms, more preferably 7 to 10 carbon atoms.The aralkyl being substituted can be replaced in the part of alkyl, aryl, or is all replaced at alkyl and aryl moiety.Representational aralkyl includes but not limited to benzyl and phenethyl and (cycloalkylaryl) alkyl (such as 4-indanyl ethyl) condensed.The representational aralkyl being substituted can be replaced once or for several times by such as substituent group listed above.
Heterocyclic radical includes the aromatic series (being also referred to as heteroaryl) containing 3 or multiple ring members and non-aromatic cyclic compound, and one or more in its ring members are hetero atoms, for instance but it is not limited to N, O and S.In some embodiments, heterocyclic radical contains 1,2,3 or 4 hetero atoms.In some instances, heterocyclic radical include having 3 to 16 ring memberses single, two and three rings.Heterocyclic radical includes loop systems aromatic, that part is unsaturated and saturated, for instance, imidazole radicals, imidazolinyl and imidazolidinyl.Phrase " heterocyclic radical " includes the ring species class condensed, these those including comprising the aromatic series condensed and non-aromatic group, for instance benzotriazole base, 2,3-dihydrobenzos [Isosorbide-5-Nitrae] dialkyl group and benzo [1,3] dioxa cyclopentenyl.This phrase also include bridging containing heteroatomic multi-loop system, for instance but be not limited to quininuclidinyl.But, this phrase does not include the heterocyclic radical with other group (such as alkyl, oxo or halo group) being bonded with one of ring members.On the contrary, these are referred to as " heterocyclic radical being substituted ".nullHeterocyclic radical includes but not limited to aziridinyl、Azetidine base、Pyrrolidinyl、Imidazolidinyl、Pyrazolidinyl、Thiazolidinyl、Tetrahydrochysene thio-phenyl、Tetrahydrofuran base、Dioxa cyclopentenyl、Furyl、Thio-phenyl、Pyrrole radicals、Pyrrolinyl、Imidazole radicals、Imidazolinyl、Pyrazolyl、Pyrazolinyl、Triazolyl、Tetrazole radical、Azoles base、Isoxazole base、Thiazolyl、Thiazolinyl、Isothiazolyl、Thiadiazole base、Di azoly、Piperidyl、Piperazinyl、Morpholinyl、Thio-morpholinyl、THP trtrahydropyranyl、Tetrahydrochysene thiopyranyl、Thioxane、Dioxane base、Dithiane base、Pyranose、Pyridine radicals、Pyrimidine radicals、Pyridazinyl、Pyrazinyl、Triazine radical、Dihydropyridine base、Dihydro two thienyl、Dihydro dithione base、Homopiperazine base、Quininuclidinyl、Indyl、Indoline base、Isoindolyl、Azaindolyl (pyrrolopyridinyl)、Indazolyl、Indolizinyl、Benzotriazole base、Benzimidazolyl、Benzofuranyl、Benzo thio-phenyl、Benzothiazolyl、Benzodiazole base、Benzimidazole dihydrochloride base、Benzo two thienyl、Benzo thienyl、Benzothiazine base、Benzoxazolyl group、Benzothiazolyl、Benzothiadiazole base、Benzo [1,3] dioxa cyclopentenyl、Pyrazolopyridine base、Imidazopyridyl (azabenzimidazoles base)、Triazolopyridine base、Isoxazole pyridine radicals、Purine radicals、Xanthinyl、Adenyl、Guanyl-、Quinolyl、Isoquinolyl、Quinolizinyl、Quinoxalinyl、Quinazolyl、Phthalazinyl、Naphthyridinyl、Thianaphthenyl、Dihydrobenzo thiazinyl、Dihydro benzo furyl、Indolinyl、Dihydrobenzo dialkyl group、Tetrahydro indole base、Tetrahydrochysene indazole base、Four benzimidazolyls、Tetrahydro benzo triazolyl、Nafoxidine pyridine radicals、Tetrahydro-pyrazole pyridine radicals、Imidazolidine pyridine radicals、Tetrahydrochysene Triazolopyridine base and tetrahydric quinoline group.The representational heterocyclic radical being substituted can through monosubstituted or be replaced and exceed once, for instance but it is not limited to that 2-, 3-, 4-, 5-or 6-replace or by such as multiple substituent group Disubstituted pyridine base listed above or morpholinyl.
Heteroaryl is the aromatic ring compound containing 5 or more ring members atom, and wherein one or more ring memberses are hetero atoms, for instance but it is not limited to N, O and S.Heteroaryl includes but not limited to following radicals, such as, pyrrole radicals, pyrazolyl, triazolyl, tetrazole radical, azoles base, isoxazole base, thiazolyl, pyridine radicals, pyridazinyl, pyrimidine radicals, pyrazinyl, thio-phenyl, benzo thio-phenyl, furyl, benzofuranyl, indyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridyl (azabenzimidazoles base), Pyrazolopyridine base, Triazolopyridine base, benzotriazole base, benzoxazolyl group, benzothiazolyl, Benzothiadiazole base, imidazopyridyl, isoxazole pyridine radicals, thianaphthenyl, purine radicals, xanthinyl, adenyl, guanyl-, quinolyl, isoquinolyl, tetrahydric quinoline group, quinoxalinyl and quinazolyl.It is all aromatic fused ring compounds that heteroaryl includes all of which ring, for instance indyl, and it also includes only one of which ring is aromatic fused ring compounds, for instance 2,3-indolinyls.Although phrase " heteroaryl " includes the cycle compound condensed, but this phrase does not include the heteroaryl with other group (such as alkyl) being bonded with one of ring members.On the contrary, the heteroaryl with this type of replacement is referred to as " heteroaryl being substituted ".The representational heteroaryl being substituted can be replaced once or for several times by such as multiple substituent group listed above.
The alkyl that cycloheteroalkylalkyl is as defined above, but wherein, the hydrogen of alkyl or carbon bond are connected the key of heterocyclic radical defined above and are replaced.The cycloheteroalkylalkyl being substituted can be replaced in the part of alkyl, heterocyclic radical, or is all replaced at alkyl and heterocyclyl moieties.Representational cycloheteroalkylalkyl includes but not limited to morpholine-4-base-ethyl, furan-2-base-methyl, imidazol-4 yl-methyl, pyridin-3-yl-methyl, oxolane-2-base-ethyl and indole-2-base-propyl group.The representational cycloheteroalkylalkyl being substituted can be replaced once or for several times by such as substituent group listed above.
The alkyl that heteroarylalkyl is as defined above, wherein, the hydrogen of alkyl or carbon bond are connected the key of heteroaryl defined above and are replaced.The heteroarylalkyl being substituted can be replaced in the part of alkyl, heteroaryl, or is all replaced at alkyl and heteroaryl moieties.The representational heteroarylalkyl being substituted can be replaced once or for several times by such as substituent group listed above.
In the compound of the present invention, the group described herein with two or more junction point (i.e. bivalence, trivalent or multivalence) is named by prefix " Asia ".Such as, divalent alkyl is alkylidene, and divalent aryl is arlydene, and divalent heteroaryl radical is heteroarylidene, etc..The group being substituted with the compound of the present invention with single point of attachment does not use " Asia " to name.It is therefoie, for example, chloroethyl is not referred to as chlorethylidene in this article.
Oxo base refers to that the group being wherein connected with oxygen atom is the alkyl being substituted or being unsubstituted, aryl, heteroaryl, cycloalkyl, alkyl acyl, aryl-acyl, heteroaroyl by the substituted radical constituted that is connected with oxygen atom.Above group is connected with oxygen atom and namely may be constructed alkoxyl, aryloxy group, heteroaryloxy, cycloalkyl oxy, alkyl acyloxy, arylacyloxy, heteroaryl acyloxy group, cycloalkyl acyloxy.
Alkoxyl is the substituent group that in hydroxyl (-OH), the key of the carbon atom that the key of connection hydrogen atom is connected alkyl that is defined above that be substituted or that be unsubstituted is replaced.The example of linear alkoxide groups includes but not limited to methoxyl group, ethyoxyl, propoxyl group, butoxy, amoxy, hexyloxy etc..The example of branched alkoxyl includes but not limited to isopropoxy, sec-butoxy, tert-butoxy, isoamoxy, different hexyloxy etc..The example of cycloalkyloxy includes but not limited to cyclopropyl oxygen, cyclobutyl oxygen, cyclopenta oxygen, cyclohexyl oxygen etc..The representational alkoxyl being substituted can be replaced once or for several times by such as substituent group listed above.
Term " alkanoyl " and " alkanoyl oxygen " refer to-C (O)-alkyl and-O-C (O)-alkyl respectively time used herein, each of which contains 2-5 carbon atom.
Term " aryl oxide " and " alkoxy aryl " refer to the substituent group that aryl that is that be substituted or that be unsubstituted is constituted with oxygen atoms bond, the substituent group that aralkyl that is that be substituted or that be unsubstituted is constituted with oxygen atoms bond respectively.Example includes but not limited to phenoxy group, naphthyl oxygen and benzyloxy.The representational aryl oxide being substituted and alkoxy aryl can be replaced once by such as substituent group listed above or for several times.
Term " carboxylic acid " refers to-COOH group time used herein.
Term " carboxylate " refers to-COOR ' group time used herein.R ' be as defined herein be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.
Term " amide " (or " amide groups ") includes C-amide group and N-amide group, is namely-C (O) NR ' R " and-NR ' C (O) R " group respectively.R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.Therefore amide groups includes but not limited to carbamoyl (-C (O) NH2) and carbonylamino group (-NHC (O) H).In some embodiments, amide is-NR ' C (O)-(C1-5Alkyl), this group is referred to as " carbonylamino ", and in other embodiments, amide is-NHC (O)-alkyl, and this group is referred to as " alkanoylamino ".
Term " nitrile " or " cyano group " refer to-CN group time used herein.
Carbaminate/ester includes N-carbamate groups and O-carbamate groups, is namely-NR ' C (O) OR " and-OC (O) NR ' R " group respectively.R ' and R " be independently as defined herein be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.R ' can also is that H.
Term " amine " (or " amino ") refer to-NR ' R time used herein " group, wherein R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.In some embodiments, amine is alkyl amino, dialkyl amido, arylamino or alkyl aryl amino.In some other embodiment, amine is NH2, methylamino, dimethylamino, ethylamino, diethylamino, propylcarbamic, isopropylamino, phenyl amino or benzylamino.
Term " sulfonamide " includes S-sulfuryl amine group and N-sulfuryl amine group, is namely-SO respectively2NR ' R " and-NR ' SO2R " group.R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.Therefore sulfuryl amine group includes but not limited to sulfonyl (-SO2NH2).In some embodiments herein, sulfonamide is-NHSO2-alkyl, it is referred to as " alkyl sulfonyl-amino ".
Term " mercaptan " refers to-SH group, and sulfide includes-SR ' group, and sulfoxide includes-S (O) R ' group, and sulfone includes-SO2R ' group, and sulfonyloxy includes-OSO2R ', sulphur acyloxy includes-OSO2OR′.R ' be independently as defined herein be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.In some embodiments, sulfide is alkylthiol groups ,-S-alkyl.
Term " urea " refers to-NR '-C (O)-NR ' R " group.R ' and R " group be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " amidine " refers to-C (NR ') NR ' R " and-NR ' C (NR ') R ", wherein, R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " guanidine " refers to-NR ' C (NR ') NR ' R ", wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " enamine " refers to-C (R ')=C (R ') NR ' R " and-NR ' C (R ')=C (R ') R ", wherein R ' and R " each be hydrogen as defined herein independently, be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " halogen " or " halo " refer to bromine, chlorine, fluorine or iodine time used herein.In some embodiments, halogen is fluorine.In some other embodiment, halogen is chlorine or bromine.
Term " hydroxyl " can refer to-OH or its ionized form-O time used herein-。
Term " acid imide " refers to-C (O) NR ' C (O) R ", wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " nitrogen heterocycle " refers to the ring system containing nitrogen-atoms, this ring system can " a pair of horses going side by side close " fragrant and non-aromatic ring system, or pass through " spiral shell carbon atom " and link other ring systems, for instance following structure:
Etc..
Term " imines " refers to-CR ' (NR ") and-N (CR ' R ") group, wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted and meet: R ' and R " different time be hydrogen.
Term " nitro " refers to-NO time used herein2。
Term " trifluoromethyl " refers to-CF time used herein3。
Term " trifluoromethoxy " refers to-OCF time used herein3。
The officinal salt of compound described herein is within the scope of the invention, it includes such acid-addition salts or base addition salts, described salt maintains intended pharmacological activity and is not have potential ill effect (such as salt does not have undue toxicity, sensitization or zest, and is bioavailable) from angle biology.When the compound of the present invention has basic group (such as, amino) time, officinal salt can be formed with mineral acid (such as hydrochloric acid, hydrogen borate, nitric acid, sulphuric acid and phosphoric acid), organic acid (such as alginate, formic acid, acetic acid, benzoic acid, gluconic acid, Fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, LOMAR PWA EINECS 246-676-2 and p-methyl benzenesulfonic acid) or acidic amino acid (such as aspartic acid and glutamic acid).When the compound of the present invention has acidic-group, for instance during hydroxy-acid group, it can with metal, for instance alkali and alkaline earth metal ions (such as Na+、Li+、K+、Ca2+、Mg2+、Zn2+), ammonia or organic amine (such as dicyclohexylamine, Trimethylamine, triethylamine, pyridine, ethanolamine, diethanolamine, triethanolamine) or basic amino acid (such as arginine, lysine and ornithine) form salt.This type of salt " one kettle way " can be prepared during to the separation of compound and purification, or can prepare this type of salt by individually being reacted with suitable acid or alkali respectively and separate the salt being consequently formed by purified to free alkali or free acid rear compound.
Well known by persons skilled in the art, the compound of the present invention can show tautomerism, conformational isomerism, geometrical isomerism and/or stereomeric phenomenon.Although the formula figure in specification and claims only represents one of possible tautomerism, conformational isomerism, stereoisomerism or geometrical isomerism form, it is understood that the present invention include compound there is any tautomerism of one or more purposes described herein, conformational isomerism, stereoisomerism and/or geometrical isomerism form and these multiple multi-form mixture.
Those skilled in the art are understandable, and large-scale functional group and other structure can show tautomer, and all tautomers of compound described herein are within.
Spatial chemistry unless specifically indicated, the stereoisomer of compound, including all chiralitys of structure, diastereo-isomerism and racemic form.Therefore, the optical isomer in the enrichment of any or all asymmetric atom place or fractionation is included for the compound in the present invention.Raceme and diastereomeric mixtures, and each optical isomer, all can separated or synthesis, to be substantially free of its corresponding isomer or diastereomer, these stereoisomers are also within the scope of the invention.
The compound of the present invention can exist as solvate, especially as hydrate.Hydrate can be formed during the manufacture of compound or the compositions of inclusion compound, or hydrate can be formed due to the hygroscopic nature of compound over time.The compound of the present invention is alternatively arranged as organic solvate to be existed, including ether and solvate etc..Qualification and preparation to any specific solvate are all that synthesis is organic or medicinal chemistry art those of ordinary skill is known.
Lipid includes that synthesize and naturally occurring fat-soluble compound, and it includes neutrality and amphiphatic molecule.Both sexes lipid typically comprises hydrophilic component and hydrophobic components.Exemplary lipid includes fatty acid, triglyceride, neutral fat, phospholipid, candy fat, fatty alcohol, wax, terpene, steroid (such as cholesterol) and surfactant.
" lipid reduction reagent " has the compound of one or more following effects when referring to be administered to patient time used herein: the liver increasing LDLR is expressed；Increase the LDLRmRNA half-life in hepatocyte；Increase the liver picked-up to blood plasma LDL, cholesterol or triglyceride；Strengthen the fatty acid oxidation of liver, reduce triglyceride synthesis and the secretion of liver, and reduce blood plasma and/or the T-CHOL of liver, LDL-cholesterol, VLDL-cholesterol or triglyceride levels.Lipid disclosed herein reduces reagent and includes the compound in the present invention.
In one aspect, the invention provides the purposes utilizing the compounds of this invention manufacture in reducing the medicine of lipid levels of patients blood plasma and/or liver, reduce compound as described herein or the compositions of effective dose including using lipid to described patient.The lipid levels reduced can be one or more in T-CHOL, LDL-cholesterol (LDL-C), triglyceride (TG) and nonesterified long-chain fatty acid.
Compound described herein and compositions can be used for preventing or treat following disease, including such as, and hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver (fatty degeneration of liver), type ii diabetes, hyperglycemia, obesity or insulin resistance and metabolism syndrome.The method for the treatment of includes compound as herein described or the compositions of the experimenter's administering therapeutic effective dose to needs treatment.The compound of the present invention can be additionally used in treatment or prevention is characterised by the blood plasma that raises or liver cholesterol or triglyceride or the morbid state relevant to the blood plasma raised or liver cholesterol or triglyceride or morbid state.The technology of the present invention also provides for using the compounds of this invention manufacture treatment or prevention disease (such as, hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver, type ii diabetes, hyperglycemia, obesity or insulin resistance or metabolism syndrome) the purposes of effective dose medicine.
Compound disclosed herein and compositions are expressed by increasing the liver of LDLR, by increasing the stability of LDLRmRNA, by increasing LDLR genetic transcription, by suppressing the degraded of the LDLR albumen that mediates of proprotein convertase subtilisin/kexin9 type (proproteinconvertasesubtilisin/kexintype9) (PCSK9) or the whole of above-mentioned possible cell mechanism, reduce lipid levels.The LDLR level increased in liver adds picked-up and the processing of blood plasma LDL-C, thus causing that the blood plasma level of cholesterol, LDL-C and triglyceride reduces.Additionally, compound can pass through to activate the AMP protein kinase (AMPK) (key molecule of bio-energy Metabolism regulation) activated increases the phosphorylation of acetyl CoA carboxylase (ACC).The phosphorylation of the increase of ACC enhances the fatty acid oxidation in liver, the TG accumulation causing liver reduces, and cause that TG secretes with VLDL form, this additionally aids the blood plasma level reducing TG, LDL-C, T-CHOL and nonesterified long-chain fatty acid, thus preventing or treating the disease relevant to hyperlipemia.On the other hand, it is believed that, hereditism and pharmaceutical research show, AMPK is that body keeps necessary to glucose balance, and compound, by activating AMPK, finally plays treatment type ii diabetes, hyperglycemia, obesity or insulin resistance or metabolism syndrome.
In yet another aspect, compound provided by the invention has increases the LDLR purposes expressed, and including to needing its compound as herein described of experimenter's administering therapeutic effective dose or compositions, thus increases the LDLR in described experimenter and expresses.In another aspect of this invention, the invention provides a kind of purposes utilizing the compounds of this invention to reduce plasma LDL-cholesterol and/or plasma triglyceride, including to needing its compound as herein described of patient therapeuticallv's effective dose or compositions, thus reduce the plasma LDL-cholesterol of described patient.
In yet another aspect, the invention provides the lipid including compound and compositions thereof and reduce reagent.Compound and compositions can be used in method and the treatment of reduction lipid as herein described.In one embodiment, the invention provides Formula V compound, its stereoisomer, its tautomer, its solvate and/or its officinal salt.
In yet another aspect, present technology provides the pharmaceutical composition comprising any compound disclosed herein and pharmaceutically suitable carrier or one or more excipient or filler and medicament.In some embodiments, it is provided that the pharmaceutical composition of the patient's condition of the group of free hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver and metabolism syndrome composition is selected in treatment.Such composition includes lipid and reduces as herein described any compound of effective dose.In one embodiment, pharmaceutical composition is packaged into unit dosage form.When being administered to the experimenter needing it, unit dosage form can effectively reduce the lipid levels (at least one in such as T-CHOL, LDL-cholesterol, triglyceride and nonesterified long-chain fatty acid) in blood flow and/or liver.
Can pass through to mix one or more compounds of the present invention, its officinal salt, its stereoisomer, its tautomer or its solvate with pharmaceutically suitable carrier, excipient, binding agent, diluent etc., prepare pharmaceutical composition, to prevent or to treat the disease relevant to the lipid levels of the blood plasma increased and/or liver.Compound as herein described can be used for preparing formulation and the medicament of the blood plasma preventing or treating and increase and/or the relevant various disease conditions (such as hyperlipemia, hypercholesterolemia, fatty degeneration of liver and metabolism syndrome) of liver lipid levels with compositions.Such composition can be the form of such as granule, powder, tablet, capsule, syrup, suppository, injection, emulsion, elixir, suspension or solution.The compositions of the present invention can be formulated for the various forms of multiple route of administration, for instance, by oral, parenteral, locally, rectum, per nasal, vaginal application or used by the storage implanted.Parenteral or systemic administration include but not limited to subcutaneous, intravenous, intraperitoneal and intramuscular, injection.Following dosage form provides as an example, and it is not necessarily to be construed as the technology of the restriction present invention.
Pharmaceutical composition containing active component can apply to the form being administered orally, for instance tablet, dragee, lozenge, water or oil suspension, dispersibles powder or granule, emulsion, hard or soft capsule, or syrup or elixir.Can refer to any known method preparing Pharmaceutical composition in this area and prepare Orally administered composition, such composition can contain one or more selected from following composition: sweeting agent, correctives, coloring agent and preservative, to provide pleasing and good to eat pharmaceutical formulation.Tablet contains active component and the suitable nontoxic pharmaceutically useful excipient preparing tablet for mixing.These excipient can be inert excipient, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate；Granulating agent and disintegrating agent, for instance microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, corn starch or alginic acid；Binding agent, for instance starch, gelatin, polyvinylpyrrolidone or arabic gum and lubricant, for instance magnesium stearate, stearic acid or Pulvis Talci.These tablets can not maybe can pass through cover the taste of medicine or postpone disintegrate and absorption in the gastrointestinal tract by coating, thus provides the known technology of slow releasing function by its coating in a long time.Such as, water soluble taste can be used to shelter material, for instance hydroxypropyl methyl cellulose or hydroxypropyl cellulose, or extend time material such as ethyl cellulose, acetylbutyrylcellulose.
Also can use wherein active component and the inert solid diluent hard gelatin capsule that such as calcium carbonate, calcium phosphate or Kaolin mix, or wherein active component provides oral formulations with water-solubility carrier such as Polyethylene Glycol or oil soluble matchmaker such as Oleum Arachidis hypogaeae semen, liquid paraffin or mixed with olive oil Perle.
Water slurry contains active substance and the suitable excipient preparing water slurry for mixing.This type of excipient is suspending agent, for instance sodium carboxy methyl cellulose, methylcellulose, hydroxypropyl methyl cellulose, sodium alginate, polyvinylpyrrolidone and arabic gum；Dispersant or wetting agent can be naturally-produced phospholipid such as lecithin, or the condensation product of alkylene oxide and fatty acid such as Myrj 45, or the condensation product of oxirane and long-chain fatty alcohol, such as 17 carbon ethyleneoxy group spermol, or oxirane and the condensation product by the derivative part ester of fatty acid and hexitol, such as polyoxyethylene sorbitol monoleate, or oxirane and the condensation product by the derivative partial ester of fatty acid and hexitan, for instance poly(ethylene oxide) Arlacel-80.Aqueous suspension can also contain one or more preservative such as ethyl hydroxybenzoate or nipalgin n-propyl, one or more coloring agent, one or more tender taste agent and one or more sweeting agents, for instance sucrose, saccharin or aspartame.
Oil suspension can pass through to make active component be suspended in vegetable oil such as Oleum Arachidis hypogaeae semen, olive oil, Oleum sesami or Oleum Cocois, or formulated in mineral oil such as liquid paraffin.Oil suspension can contain thickening agent, for instance Cera Flava, hard paraffin or spermol.Above-mentioned sweeting agent and tender taste agent can be added, to provide good to eat preparation.These compositionss can be preserved by addition antioxidant such as butylated hydroxyanisole or alpha-tocopherol.
Can make to be applicable to prepare water suspendible dispersible powder and granule also provide active component and for the dispersant mixed or wetting agent, suspending agent or one or more preservative by adding water.Suitable dispersant or wetting agent and suspending agent can illustrate above-mentioned example.Also other excipients such as sweeting agent, tender taste agent and coloring agent can be added.These compositionss are preserved by adding antioxidant such as ascorbic acid.
The pharmaceutical composition of the present invention can also be the form of oil in water emulsion.Oil phase can be vegetable oil such as olive oil or Oleum Arachidis hypogaeae semen, or mineral oil such as liquid paraffin or its mixture.Suitable emulsifying agent can be naturally-produced phospholipid, for instance soybean lecithin and by the derivative ester of fatty acid and hexitan or partial ester such as sorbitan monooleate, and the condensation product of described partial ester and oxirane, for instance polyoxyethylene sorbitol monoleate.Emulsion can also contain sweeting agent, tender taste agent, preservative and antioxidant.Available Sweetening agents such as glycerol, propylene glycol, sorbitol or sucrose syrup blend and elixir.This type of preparation also can contain demulcent, preservative, coloring agent and antioxidant.
Pharmaceutical composition can be sterile injectable aqueous form.Water, ringer's solution and isotonic sodium chlorrde solution can be had in the acceptable solvent used and solvent.Aseptic injection preparation can be that wherein active component is dissolved in the aseptic injection oil-in-water microemulsion of oil phase.Such as active component is dissolved in the mixture of soybean oil and lecithin.Then oil solution is added process in the mixture of water and glycerol and forms microemulsion.The a large amount of injection in local can be passed through, injection or microemulsion are injected in the blood flow of patient.Or, it is desirable to solution and microemulsion is given by the mode that can keep the compounds of this invention constant circulating concentration.For keeping this constant density, continuous intravenous delivery device can be used.
Pharmaceutical composition could be for the aseptic injection water of intramuscular and subcutaneous administration or the form of oil suspension.Can by known technology, the dispersant suitable by those described above or wetting agent and suspending agent prepare this suspension.Aseptic injection preparation can also be aseptic injectable solution or the suspension of preparation in the acceptable diluent of nontoxic parenteral or solvent, for instance the solution of preparation in 1,3 butylene glycol.In addition, it is convenient to aseptic fixing oil as solvent or suspension media.For this purpose it is proposed, the fixing oil of any mediation including synthetic glycerine list or diester can be used.Additionally, fatty acid such as oleic acid can also prepare injection.
Dosage form for local (including buccal and Sublingual) or the compound of the transdermal administration present invention includes powder, spraying, ointment, paste, emulsifiable paste, washing liquid, gel, solution and paster.Active component can aseptically with pharmaceutically suitable carrier or excipient and be likely to any preservative of needing or buffer agent mixes.Powder and spraying can such as be prepared with excipient (such as the mixture of sugar, Muscovitum, silicic acid, sodium hydroxide, calcium silicates and polyamine powder or these materials).Ointment, paste, emulsifiable paste and gel also can contain following excipient, for instance, animal and plant fat, oil, wax, paraffin, starch, tragacanth, cellulose derivative, Polyethylene Glycol, silicone, bentonite, silicic acid, Muscovitum and zinc oxide or its mixture.It is also possible to use absorption enhancer, the compound increasing the present invention penetrates the flowing of skin.By providing rate controlling membranes (such as a part for percutaneous plaster) or compound can be scattered in the speed controlling this type of flowing in polymeric matrix or gel.
The compounds of this invention can be given by the suppository form for rectally.Can pass through by medicine be solid at normal temperatures but in the rectum for liquid, thus can dissolve in the rectum and discharge the suitable nonirritant excipient of medicine and mix and prepare these pharmaceutical compositions.This type of material includes the mixture of the fatty acid ester of cocoa butter, glycerin gelatine, hydrogenated vegetable oil, the Polyethylene Glycol of various molecular weight and Polyethylene Glycol.
The compound of the present invention also can be used together with can be used for treating or prevent other traditional treatment agent of hyperlipemia disease.For including but not limited to that anti-inflammatory medicine, therapeutic antibodies and cholesterol reduce medicine with the exemplary treatment reagent of the combination treatment of one or more compounds of the present invention, for instance, statin.Can be used for the useful additional treatment reagent of formulated in combination thing and cooperation treatment to include, for instance, anti-hyperlipidemia reagent；Antilipemic exception reagent；Anti-diabetic reagent, includes but not limited to cholesteral biosynthesis inhibitor, for instance HMG-CoA reductase inhibitor (is also referred to as statin, lovastatin, simvastatin, pravastatin, fluvastatin, Rosuvastatin, Pitavastatin and atorvastatin)；HMG-CoA reduces synthase inhibitor；Squalene epoxidase inhibitor or inhibitor for squalene synthetic enzyme (being also known as squalene synthase inhibitor)；Microsomal triglyceride transfer protein (MTP) inhibitor；Cholic acid chelating agent anion exchange resin, includes but not limited to cholestyramine, cholestipol, the dialkylaminoalkyl derivative of colesevelam or crosslinked glucosan；Ldl receptor derivant；Fibrates, includes but not limited to clofibrate, bezafibrate, fenofibrate and gemfibrozil；Metformin, rosiglitazone, blood plasma HDL-elevating agent, include but not limited to nicotinic acid, fibrates；Anti-hypercholesterolemiccompounds reagent, includes but not limited to cholesterol-uptake inhibitor；Acyl-coenzyme a cholesterol acyltransferase (ACAT) inhibitor, includes but not limited to that amine of Merrill Lynch；Probucol；Nicotinic acid and salt thereof；Nicotiamide；Cholesterol absorption inhibitor, includes but not limited to cupreol or ezetimibe；Vitamin B6 (pyridoxol) and officinal salt thereof, for instance HCl salt；Vitamin B12(cobalamin)；Vitamin B3(nicotinic acid and nicotiamide)；Antioxidant vitamin, includes but not limited to vitamin C and vitamin E and bata-carotene；Beta receptor blockers；Angiotensin-ii receptor (AT1) antagonist；Angiotensin-convertion enzyme inhibitor, renin inhibitor；Anticoagulant, includes but not limited to fibrinogen deceptor antagonists, i.e. glycoprotein iib/iiia fibrinogen deceptor antagonists；Hormone, includes but not limited to estrogen；Insulin；Ion exchange resin；Ω-3 oil；Benfluorex；26 carbon 5 alkene acid ethyl ester and amlodipine.Adjunctive therapy may also include increase exercise, operation and change meals (such as becoming low cholesterol diet) some plant medicineses and also can be effectively used for formulated in combination thing and cooperation therapy, to treat hyperlipemia, for instance curcumin, balosam sterone, Bulbus Allii, Semen sojae atricolor, soluble fiber, fish oil, green tea, carnitine, chromium, coenzyme Q10, Semen Vitis viniferae extract, dimerization pantothenic acid, Monas cuspurpureus Went and Lac regis apis.
Berberine and related compound also can treat reagent as second, reduce with the lipid of the present invention together with reagent and use.Such as; berberine sulfate, berberine hydrochloride, berberine chloride, oxygen berberine, dihydroberberine, 8-cyano group dihydroberberine, N-1 N-oxide, N-1, protoberberine, 9-ethoxy carbonyl berberine, 9-N, N-formyl-dimethylamino berberine and 12-bromo berberine, berberine azide and berberine glycine betaine can be used.
Also can modify the compound of the present invention, for instance couple organic structure fragment by covalency or conjugate carries out, to improve pharmacokinetic property, toxicity or bioavailability (Half-life in vivo such as increased).Conjugate can be linear or branched hydrophilic polymer group, fatty acid group or fatty acid ester group.Polymer-based group can comprise the molecular weight that can be regulated by those skilled in the art, to improve, for instance pharmacokinetic property, toxicity or bioavailability.Exemplary conjugate can include poly-alkanol (such as Polyethylene Glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinylpyrrolidone and fatty acid or fatty acid ester group, each of which can independently comprise about 8 to about 70 carbon atoms.Conjugate for using together with the compound of the present invention also acts as joint, for instance for any suitable substituent group or group, radioactive label (mark or label), halogen, albumen, enzyme, polypeptide, other treatment reagent (such as medicine or medicine), nucleoside, dyestuff, oligonucleotide, lipid, phospholipid and/or liposome.In one aspect, conjugate can include polyvinylamine (PEI), polyglycine, PEI and the crossbred of polyglycine, Polyethylene Glycol (PEG) or methoxy poly (ethylene glycol) (mPEG).The compound of the present invention also can be connected to by conjugate, for instance, labelling (that fluoresce or luminescence) or mark (radioactivity element, radiosiotope and/or isotope), to comprise the probe of the present invention.The conjugate used together with the compound of the present invention can improve Half-life in vivo in one aspect.
Term " link " and/or " combination " can represent and chemically or physically interact, for instance between compound and the target interested of the present invention.The example linked or interact includes covalent bond, ionic bond, hydrophilic-hydrophobic interacts, hydrophobic-hydrophobic interacts and complex." link " generally also may be referred to " combination " or " affinity ", and each of which is used equally to describe and multiple chemically or physically interacts.Measurement combination or affinity are also the routine techniquess of those skilled in the art.
Provided herein is the following examples to set forth advantages of the present invention, and assist those of ordinary skill in the art's preparation further or use the compound or its salt of the present invention, pharmaceutical composition, derivant, metabolite, prodrug, racemic mixture or tautomeric form.The embodiments herein is additionally operable to set forth preferred aspect of the present invention.Embodiment is not construed in any way as limiting the scope of the present invention defined by the appended claims.
Detailed description of the invention
The conventional method of the present invention explained further below, the compound of the present invention can be prepared by method as known in the art, is described in detail for the preparation method of preferred compounds of the invention below but the preparation method of the compounds of this invention is not limited to this.
General formula compound disclosed by the invention (V) preparation is prepared essentially according to following scheme:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound V by connecting.
Now for synthetically prepared flow process representative in patent of the present invention, introducing general formula compound (V) and prepare scheme, the compounds of this invention is prepared scheme and is not limited to following representative flow process:
Representative flow process one: for the compound of r=0 in general formula compound (V):
Scheme 1:
X1 and X3 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X3 under certain reaction condition, under certain alkaline reagent existent condition, prepare V-1 by nucleophilic substitution.
Scheme 2:
X1 and X4 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X4 under certain reaction condition, prepare V-1 by the reaction of reduction amination.
Representative flow process two: for the compound of r=1 in general formula compound (V):
Scheme 3:
X1 and X5 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By X1 and X5 under certain reaction condition, under certain alkaline reagent existent condition, prepare V-2 by coupled reaction.
Further, formula (VI):
Y1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VI by connecting.
Further, formula (VII):
K1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.K1 and X2 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VII by connecting.
Further, formula (VIII):
X1 and L1 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and L1 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound VIII by connecting.
Further, formula (IX):
K1 and Z1 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.K1 and Z1 is when certain reaction temperature, under certain alkaline reagent existent condition, obtains compound IX by connecting.
Now for synthetically prepared flow process representative in patent of the present invention, introducing general formula compound (VIII) and prepare scheme, the compounds of this invention is prepared scheme and is not limited to following representative flow process:
Representative flow process one: for the compound of r=0 in general formula compound (IX):
Scheme 1:
K1 and Z2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z2 under certain reaction condition, under certain alkaline reagent existent condition, prepare IX-1 by nucleophilic substitution.
Scheme 2:
K1 and Z3 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z3 under certain reaction condition, prepare IX-1 by the reaction of reduction amination.
Representative flow process two: for the compound of r=1 in general formula compound (VIII):
Scheme 3:
K1 and Z4 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.By K1 and Z4 under certain reaction condition, under certain alkaline reagent existent condition, prepare IX-2 by coupled reaction.
Further illustrate the present invention below by specific embodiment, but those skilled in the art are it should be understood that the present invention is not limited in these embodiments.
The structure of compound is determined by nuclear magnetic resonance, NMR (NMR) or mass spectrum (MS).The mensuration of NMR is to use BrukerAVANCE-400 nuclear magnetic resonance spectrometer, and measuring solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterochloroform (CDCl3), deuterated methanol (CD3OD), being inside designated as tetramethylsilane (TMS), chemical shift is with 10-6(ppm) provide as unit.
The mensuration of MS is with FINNIGANLCQAd (ESI) mass spectrograph (manufacturer: Thremo model: FinniganLCQadvantageMAX)
Tlc silica gel plate uses Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plate, and the specification of the silica gel plate that thin layer chromatography (TLC) uses is 0.15mm～0.2mm, and the specification that thin layer chromatography separation purified product adopts is 0.4mm～0.5mm silica gel plate.
It is carrier that column chromatography generally uses the Yantai Huanghai Sea 200～300 order silica gel.
The known initiation material of the present invention can adopt or synthesize according to methods known in the art, or commercially available from GmbH&Co.KG, AcrosOrgannics, AldrichChemicalCompany, TCIChemicals, pacifies the Xue Deng of resistance to Jilin Chemical company.
In embodiment if no special instructions, reaction all carries out under argon atmospher or blanket of nitrogen.
Argon atmospher or blanket of nitrogen refer to that reaction bulb connects argon ball or the nitrogen ball of an about 1L volume.
Nitrogen atmosphere refers to that reaction bulb connects the hydrogen balloon of an about 1L volume.
The normal evacuation of hydrogenation, is filled with hydrogen, repeatable operation 3 times.
In embodiment if no special instructions, the temperature of reaction is room temperature, and temperature range is 20 DEG C～30 DEG C
The monitoring of the reaction process in embodiment adopts thin layer chromatography (TLC), the system of the developing solvent that reaction uses has: A: dichloromethane and methanol system, B: normal hexane and ethyl acetate system, C: normal hexane and acetone system, D: normal hexane, E: ethyl acetate, the volume ratio of solvent is adjusted according to the polarity difference of compound, it is also possible to add a small amount of triethylamine and acidity or alkaline reagent etc. are adjusted.
The system of the system of the eluant of the column chromatography that purifying compounds adopts and the developing solvent of thin layer chromatography includes: A: dichloromethane and methanol system, B: normal hexane and ethyl acetate system, C: normal hexane and acetone system, D: normal hexane, E: ethyl acetate, the volume ratio of solvent is adjusted according to the polarity difference of compound, it is also possible to add a small amount of triethylamine and acidity or alkaline reagent etc. are adjusted.
Embodiment 1
50mL round-bottomed flask adds 1A (242mg, 0.951mmol), it is dissolved in dichloromethane (10mL), adds triethylamine (331 μ L, 2.38mmol), stirring 5min, add compound 1B (126 μ L, 0.951mmol), stirred at rt for another 2h, separate purification through silica gel column chromatography (dichloromethane: methanol 50:1) after concentration and obtain white solid product 1 (27mg, productivity 6.9%).1HNMR(400MHz,CDCl3) δ 7.52 4.47 (m, 1H), 7.47 7.36 (m, 2H), 7.29 7.10 (m, 5H), 7.03 6.98 (m, 1H), 6.83 (d, J=2.5Hz, 1H), 6.76 (dd, J=8.5,2.6Hz, 1H), 6.68 (d, J=8.5Hz, 1H), 3.80 (s, 2H), 3.72 (s, 2H), 2.94 (t, J=5.6Hz, 2H), 2.88 2.76 (m, 2H)；MS(ESI)m/z[M+H]+: 413.34.
Embodiment 2
100mL round-bottomed flask adds sodium hydroxide (8g), dissolves with water (50mL), be cooled to room temperature, add 2A (10.0g, 0.066mol), stirring and dissolving, it is dividedly in some parts 2B (12.6g, 0.066mol), stirred overnight at room temperature again.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitate out solid, sucking filtration, washing, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, sucking filtration, filtrate regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitates out solid, sucking filtration, washing, dried white solid 2C (7.05g, productivity 36.5%).
100mL round-bottomed flask adds 2C (500mg, 1.71mmol), dichloromethane (20mL) dissolves, add methylchloroformate (146 μ L, 1.88mmol), triethylamine (285 μ L, 2.05mmol), 2h is stirred at room temperature, add 2D (432mg, 1.88mmol), triethylamine (285 μ L, 2.05mmol), stir overnight under room temperature, evaporated under reduced pressure solvent, it is dissolved in water, extraction into ethyl acetate, merge organic facies, washing, anhydrous sodium sulfate dries, separate purification through silica gel column chromatography (dichloromethane: methanol 100:1) after concentration and obtain white paste product 2 (320mg, productivity 40.0%).1HNMR(400MHz,CDCl3)δ7.71–7.63(m,2H),7.47–7.27(m,5H),7.23–7.17(m,1H),6.65–6.61(m,1H),6.60–6.37(m,1H),4.81–4.42(m,3H),3.92–3.75(m,6H),3.58–3.33(m,2H),2.95–2.59(m,2H),2.46–2.38(m,3H)；MS(ESI)m/z[M+H]+: 468.29.
Embodiment 3
50ml two neck bottle adds sodium hydride (434mg, 18.1mmol), adds oxolane (3.5ml), nitrogen protection.Under room temperature under stirring, the tetrahydrofuran solution of injection dropping compound 3A (1000mg, 7.24mmol).After stirring 1h under room temperature, the tetrahydrofuran solution of injection dropping compound 3B (1238mg, 7.24mmol).After continuing stirring reaction 24h under room temperature, reactant liquor is added in frozen water, after dichloromethane extraction, water layer hydrochloric acid (1M) adjusts PH to about 2, then with dichloromethane extraction, merges organic layer, saturated sodium-chloride water solution is washed, anhydrous magnesium sulfate dries, and concentration, in ethanol, recrystallization obtains yellow needle-like crystals 3C.
25ml round-bottomed flask adds compound 3C (343mg; 1mmol); compound 3D (250mg; 1.3mmol), 3A molecular sieve (375mg), toluene (5ml); acetic acid (78.6mg; 1.3mmol), nitrogen protection, 80 DEG C of stirring reaction 1h.Reaction system being down to room temperature, adds ammonium formate (409mg, 6.5mmol) palladium carbon (50mg), stir 30min, filter under room temperature, ethyl acetate is washed.Filtrate is washed with saturated sodium bicarbonate aqueous solution, merges organic layer anhydrous magnesium sulfate and dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1), for eluant, obtains white solid product 3 (148mg, productivity: 43.1%).1HNMR (500MHz, Chloroform) δ 7.51 7.44 (m, 2H), 7.43 7.35 (m, 3H), 7.31 (dd, J=11.8,10.9Hz, 2H), 7.22 7.13 (m, 3H), 6.44 (dd, J=7.6,4.9Hz, 2H), 5.27 (s, 2H), 4.68 (s, 1H), 3.68 (d, J=20.0Hz, 4H), 2.96 (td, J=11.7,1.4Hz, 2H), 2.79 (td, J=11.7,1.4Hz, 2H)；MS(ESI)m/z[M+H]+: 346.35.
Embodiment 4
25ml round-bottomed flask adds compound 4A (204mg; 1.3mmol); compound 4B (300mg; 1.7mmol), 3A molecular sieve (450mg), toluene (5ml); acetic acid (102mg; 1.7mmol), nitrogen protection, 80 DEG C of stirring reaction 1h.Reaction system being down to room temperature, adds ammonium formate (535mg, 8.5mmol) palladium carbon (60mg) and at room temperature stir 30min, filter, ethyl acetate is washed.Filtrate is washed with saturated sodium bicarbonate aqueous solution, merges organic layer anhydrous magnesium sulfate and dries, through silica gel column chromatography after concentration, with dichloromethane: methanol (15:1), for eluant, obtains yellow oil product 4 (103mg, productivity: 26.4%).1HNMR(500MHz,Chloroform)δ7.39–7.30(m,1H),7.26–7.16(m,1H),6.98–6.86(m,2H),6.85–6.70(m,3H),3.83(s,3H),3.81(s,1H),3.76(s,1H),3.66(s,2H),2.90–2.79(m,2H),2.78–2.68(m,2H)；MS(ESI)m/z[M]+: 308.32.
Embodiment 5
25ml round-bottomed flask adds compound 5A (200mg, 1.23mmol), compound 5B (273mg, 1.11mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (284mg, 1.34mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (4:1) is for eluant, obtain white solid product 5 (186mg, productivity: 42.7%).1HNMR(400MHz,CDCl3) δ 8.24 (dd, J=7.9,1.2Hz, 1H), 7.89 7.78 (m, 2H), 7.75 (d, J=7.2Hz, 1H), 7.55 (td, J=7.6,1.3Hz, 1H), 7.50 7.38 (m, 2H), 7.29 (dd, J=10.8,4.8Hz, 2H), 6.80 (d, J=8.4Hz, 1H), 6.65 (dd, J=8.4,2.6Hz, 1H), 6.55 (d, J=2.5Hz, 1H), 3.91 (s, 2H), 3.73 (s, 3H), 3.39 (s, 2H), 2.56 (s, 2H), 2.43 (t, J=5.9Hz, 2H)；MS(ESI)m/z[M+H]+: 394.06.
Embodiment 6
25ml round-bottomed flask adds compound 6A (254mg, 1.32mmol), compound 6B (331mg, 1.20mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (304mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (7:1) is for eluant, obtain white solid product 6 (179mg, productivity: 33.1%).1HNMR(400MHz,CDCl3) δ 7.78 (d, J=8.2Hz, 2H), 7.67 7.55 (m, 1H), 7.38 7.16 (m, 4H), 7.07 (d, J=7.7Hz, 1H), 6.61 (s, 1H), 6.48 (s, 1H), 3.85 (s, 3H), 3.84 (s, 3H) 3.56 (s, 2H), 3.48 (s, 2H), 2.80 (t, J=5.7Hz, 2H), 2.65 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+,454.13。
Embodiment 7
50mL round-bottomed flask adds compound 7A (90mg, 0.376mmol), chloroform (5mL), between fluorophenylsulfonyl chloride 7B (125 μ L, 0.940mmol), pyridine (0.5mL), 65 DEG C of oil baths are reacted 2.5h, evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merging organic facies, washing, anhydrous sodium sulfate dries, separate purification through preparation TLC (petroleum ether: ethyl acetate 5:1) after concentration and obtain white solid 7 (21mg, productivity 14.1%).1HNMR(400MHz,CDCl3) δ 7.80 7.75 (m, 1H), 7.73 7.67 (m, 1H), 7.53 (td, J=8.1,5.3Hz, 1H), 7.41 7.33 (m, 1H), 7.28 7.17 (m, 2H), 7.16 7.06 (m, 3H), 7.00 6.95 (m, 1H), 6.79 (dd, J=7.7,1.6Hz, 1H), 3.78 (s, 2H), 3.62 (s, 2H), 3.52 (s, 3H), 2.89 (t, J=5.8Hz, 2H), 2.73 (t, J=5.9Hz, 2H)；MS(ESI)m/z[M+H]+: 428.29.
Embodiment 8
50mL round-bottomed flask adds compound 8A (150mg, 0.558mmol), chloroform (5mL), 8B (297 μ L, 2.23mmol), pyridine (0.5mL), 65 DEG C of oil baths are reacted 2.5h, evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merging organic facies, washing, anhydrous sodium sulfate dries, separate purification through silica gel column chromatography (petroleum ether: ethyl acetate 10:1) after concentration and obtain light yellow oil 8 (170mg, productivity 71.3%).1HNMR(400MHz,CDCl3) δ 7.72 7.66 (m, 1H), 7.64 7.58 (m, 1H), 7.50 (td, J=8.1,5.3Hz, 1H), 7.39 7.32 (m, 1H), 7.19 7.08 (m, 4H), 7.04 6.96 (m, 2H), 6.93 6.86 (m, 1H), 3.73 3.66 (m, 4H), 3.55 (s, 3H), 2.92 (t, J=5.8Hz, 2H), 2.81 (t, J=5.9Hz, 2H).
Embodiment 9
50mL round-bottomed flask adds compound 9A (150mg, 0.558mmol), chloroform (5mL), 9B (297 μ L, 2.23mmol), pyridine (0.5mL), 65 DEG C of oil baths are reacted 2.5h, evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merging organic facies, washing, anhydrous sodium sulfate dries, separate purification through silica gel column chromatography (petroleum ether: ethyl acetate 10:1) after concentration and obtain light yellow oil 9 (183mg, productivity 76.8%).1HNMR(400MHz,CDCl3) δ 7.67 7.59 (m, 2H), 7.45 (td, J=8.1,5.3Hz, 1H), 7.38 7.27 (m, 2H), 7.24 7.20 (m, 1H), 7.20 7.09 (m, 3H), 7.03 6.98 (m, 1H), 6.84 (d, J=8.4Hz, 1H), 3.83 3.75 (m, 4H), 3.57 (s, 3H), 3.00 2.89 (m, 4H).
Embodiment 10
50mL round-bottomed flask adds 10A (100mg, 0.376mmol), it is dissolved in dichloromethane (10mL), adds triethylamine (78 μ L, 0.563mmol), stirring 5min, adds compound 10B (60 μ L, 0.451mmol), stirred at rt for another 2h, evaporated under reduced pressure solvent, separates purification through silica gel column chromatography (dichloromethane: methanol 50:1) and obtains white solid 10 (27mg, productivity 12.3%).1HNMR(400MHz,CDCl3) δ 8.39 (brs, 1H), 7.65 7.32 (m, 7H), 7.32 6.84 (m, 8H), 4.67 (d, J=3.4Hz, 1H), 4.60 4.10 (m, 1H), 3.59 3.04 (m, 2H), 3.02 2.60 (m, 2H)；MS(ESI)m/z[M+H]+,584.94。
Separate purification through post silica gel column chromatography (dichloromethane: methanol 50:1) and obtain white solid 11 (69mg, productivity 43.3%).1HNMR(400MHz,CDCl3) δ 7.58 7.27 (m, 4H), 7.26 6.89 (m, 5H), 6.70 6.64 (m, 1H), 6.58 (dd, J=15.6,2.9Hz, 1H), 4.77 4.27 (m, 2H), 3.83 (brs, 2H), 3.63 3.36 (m, 2H), 3.04 2.68 (m, 2H)；MS(ESI)m/z[M+H]+: 426.99.
Embodiment 12
25ml round-bottomed flask adds compound 12A (300mg, 1.26mmol), potassium carbonate (348mg, 2.52mmol), DMF (2ml), stirring is simultaneously introduced compound 12B (322mg, 1.88mmol).60 DEG C of stirring reactions, it is complete that TLC detects raw material reaction, reaction system is concentrated, and through preparation TLC purification (petroleum ether: ethyl acetate 5:1), obtains colorless oil as product 12 (258mg, productivity: 62.2%).1HNMR(400MHz,CDCl3) δ 7.48 (s, 3H), 7.40 (s, 4H), 7.30 (t, J=10.0Hz, 4H), 7.20 (s, 4H), 6.92 (d, J=5.0Hz, 3H), 6.85 (s, 1H), 5.16 (s, 3H), 3.70 (s, 3H), 3.66 (s, 3H), 2.96 (s, 2H), 2.79 (s, 2H)；MS(ESI)m/z[M]+: 329.21.
Embodiment 13
25ml round-bottomed flask adds compound 13A (200mg, 1.68mmol), compound 13B (446mg, 1.52mmol), ethyl acetate (3ml), adds sodium triacetoxy borohydride (387mg, 1.82mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 13 (272mg, productivity: 45.3%).1HNMR(400MHz,CDCl3) δ 7.92 (d, J=7.5Hz, 2H), 7.67 (t, J=7.5Hz, 1H), 7.54 (t, J=7.8Hz, 2H), 7.19 7.05 (m, 3H), 6.91 (d, J=8.0Hz, 2H), 6.72 (t, J=7.3Hz, 1H), 6.48 (d, J=7.8Hz, 1H), 4.21 (s, 2H), 3.53 (s, 3H), 3.32 (t, J=8.3Hz, 2H), 3.01 (t, J=8.2Hz, 2H)；MS(ESI)m/z[M+H]+: 396.09.
Embodiment 14
The scheme of reference example 6 and pertinent literature prepare compound 14, MS (ESI) m/z [M+H]+: 440.20.
Embodiment 15
25ml round-bottomed flask adds compound 15A (100mg, 0.36mmol), compound 15B (280mg, 1.44mmol), pyridine (114mg, 1.44mmol) and dichloromethane (2ml), at room temperature stirs 4h.Reaction system is concentrated after reacting completely by TLC detection, through silica gel column chromatography, with petroleum ether: ethyl acetate (5:1), for eluant, obtains white solid product 15 (87mg, productivity: 55.4%).1HNMR(400MHz,CDCl3) δ 7.74 (s, 1H), 7.69 7.57 (m, 3H), 7.49 (d, J=7.5Hz, 1H), 7.43 7.38 (m, 1H), 7.36 7.24 (m, 5H), 7.18 7.09 (m, 3H), 3.69 (s, 2H), 3.65 (s, 2H), 2.87 (t, J=5.4Hz, 2H), 2.81 (d, J=5.1Hz, 2H)；MS(ESI)m/z[M+H]+: 437.96.
Embodiment 16
25ml round-bottomed flask adds compound 16A (254mg, 1.32mmol), compound 16B (336mg, 1.20mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (304mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 16 (231mg, productivity: 42.1%).1HNMR(400MHz,CDCl3) δ 7.73 (d, J=7.8Hz, 1H), 7.68 7.57 (m, 2H), 7.51 (td, J=8.1,5.3Hz, 1H), 7.43 7.34 (m, 1H), 7.33 7.20 (m, 2H), 7.08 (dd, J=7.9,1.3Hz, 1H), 6.61 (s, 1H), 6.48 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.58 (s, 2H), 3.49 (s, 2H), 2.81 (t, J=5.7Hz, 2H), 2.67 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+: 458.04.
Embodiment 17
25ml round-bottomed flask adds compound 17A (254mg, 1.32mmol), compound 17B (372mg, 1.20mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (304mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 17 (225mg, productivity: 38.5%).1HNMR(400MHz,CDCl3) δ 7.69 (d, J=7.7Hz, 1H), 7.63 (d, J=7.9Hz, 1H), 7.46 (dd, J=13.4,8.0Hz, 1H), 7.34 (t, J=8.3Hz, 1H), 7.27 (d, J=8.5Hz, 1H), 7.22 (s, 1H), 6.84 (d, J=8.4Hz, 1H), 6.62 (s, 1H), 6.51 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.60 (s, 5H), 3.52 (s, 2H), 2.82 (t, J=5.5Hz, 2H), 2.71 (t, J=5.7Hz, 2H)；MS(ESI)m/z[M+H]+: 488.09.
Embodiment 18
25ml round-bottomed flask adds compound 18A (254mg, 1.32mmol), compound 18B (367mg, 1.20mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (304mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 18 (264mg, productivity: 45.5%).1HNMR(400MHz,CDCl3) δ 7.76 (d, J=8.3Hz, 2H), 7.31 7.22 (m, 3H), 7.16 (d, J=1.9Hz, 1H), 6.83 (d, J=8.4Hz, 1H), 6.62 (s, 1H), 6.51 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.62 (s, 2H), 3.60 (s, 3H), 3.54 (s, 2H), 2.83 (t, J=5.6Hz, 2H), 2.74 (t, J=5.6Hz, 2H), 2.42 (s, 3H)；MS(ESI)m/z[M+H]+: 484.17.
Embodiment 19
25ml round-bottomed flask adds compound 19A (254mg, 1.32mmol), compound 19B (372mg, 1.20mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (304mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 19 (231mg, productivity: 39.6%).1HNMR(400MHz,CDCl3) δ 7.80 (d, J=8.3Hz, 2H), 7.32 (d, J=8.2Hz, 2H), 7.11 (d, J=8.1Hz, 1H), 6.98 (d, J=1.3Hz, 1H), 6.90 (dd, J=8.1,1.4Hz, 1H), 6.63 (s, 1H), 6.53 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.64 (s, 2H), 3.59 (s, 3H), 3.56 (s, 2H), 2.84 (t, J=5.7Hz, 2H), 2.72 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+: 488.17.
Embodiment 20
25ml round-bottomed flask adds compound 20A (200mg, 1.16mmol), compound 20B (310mg, 1.06mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (269mg, 1.29mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1) is for eluant, colorless oil as product 20 (136mg, productivity: 28.7%).1HNMR(400MHz,CDCl3) δ 7.94 7.79 (m, 3H), 7.73 (d, J=2.3Hz, 1H), 7.72 7.64 (m, 2H), 7.39 7.30 (m, 1H), 7.21 (dd, J=10.4,7.6Hz, 1H), 6.98 6.87 (m, 2H), 6.81 (dd, J=8.9,6.0Hz, 2H), 6.63 (dd, J=15.0,2.9Hz, 1H), 3.83 (s, 3H), 3.81 (s, 1H), 3.75 (s, 1H), 3.60 (s, 2H), 2.84 (t, J=5.8Hz, 2H), 2.72 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M-H]-: 447.12.
Embodiment 21
25ml round-bottomed flask adds compound 21A (212mg, 1.1mmol), compound 21B (214mg, 1.0mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (254mg, 1.2mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 21 (158mg, productivity: 40.3%).1HNMR(400MHz,CDCl3) δ 7.59 (d, J=7.6Hz, 1H), 7.33 7.27 (m, 6H), 7.26 7.19 (m, 2H), 6.62 (s, 1H), 6.50 (s, 1H), 3.87 (s, 3H), 3.85 (s, 2H), 3.84 (s, 3H), 3.60 (s, 2H), 2.84 (t, J=5.5Hz, 2H), 2.78 (t, J=5.4Hz, 2H)；MS(ESI)m/z[M+H]+: 392.42.
Embodiment 22
25ml round-bottomed flask adds compound 22A (212mg, 1.1mmol), compound 22B (350mg, 1.0mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (254mg, 1.2mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (4:1) is for eluant, obtain white solid product 22 (187mg, productivity: 35.7%).1HNMR(400MHz,CDCl3) δ 7.81 (d, J=8.2Hz, 2H), 7.29 (d, J=8.2Hz, 3H), 6.59 (s, 1H), 6.53 (dd, J=8.7,2.3Hz, 1H), 6.48 (s, 1H), 6.26 (d, J=2.3Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.45 (d, J=7.6Hz, 4H), 3.23 (q, J=7.0Hz, 4H), 2.78 (t, J=5.5Hz, 2H), 2.64 (t, J=5.7Hz, 2H), 2.43 (s, 3H), 1.08 (t, J=7.0Hz, 6H)；MS(ESI)m/z[M+H]+: 525.22.
Embodiment 23
25ml round-bottomed flask adds compound 23A (222mg, 1.15mmol), compound 23B (400mg, 1.04mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (265mg, 1.25mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (8:1) is for eluant, obtain white solid product 23 (248mg, productivity: 42.6%).1HNMR(400MHz,CDCl3) δ 7.74 (d, J=8.2Hz, 2H), 7.31 (s, 1H), 7.22 (d, J=8.1Hz, 2H), 7.06 (s, 1H), 6.64 (s, 1H), 6.54 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.66 (s, 2H), 3.62 (s, 3H), 3.59 (s, 2H), 2.80 (t, J=5.6Hz, 2H), 2.75 (t, J=5.6Hz, 2H), 2.40 (s, 3H)；MS(ESI)m/z[M]+: 561.08.
Embodiment 24
25ml round-bottomed flask adds compound 24A (218mg, 1.13mmol), compound 24B (200mg, 1.03mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (263mg, 1.24mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 24 (130mg, productivity: 34.1%).1HNMR(400MHz,CDCl3) δ 7.22 (dd, J=10.2,5.1Hz, 1H), 7.16 (dd, J=8.6,3.5Hz, 1H), 7.06 (s, 1H), 7.03 7.01 (m, 1H), 6.91 (dd, J=8.2,3.5Hz, 1H), 6.63 (s, 1H), 6.53 (s, 1H), 3.89 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.66 (s, 2H), 2.85 (dd, J=9.8,4.4Hz, 4H)；MS(ESI)m/z[M+H]+: 372.00.
Embodiment 25
25ml round-bottomed flask adds compound 25A (238mg, 1.23mmol), compound 25B (225mg, 1.12mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (235mg, 1.35mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain colorless oil as product 25 (211mg, productivity: 44.5%).1HNMR(400MHz,CDCl3) δ 8.01 7.96 (m, 2H), 7.92 (d, J=8.4Hz, 2H), 7.63 7.49 (m, 5H), 6.61 (s, 1H), 6.48 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.72 (s, 2H), 3.54 (s, 2H), 2.83 (t, J=5.7Hz, 2H), 2.73 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+: 424.14.
Embodiment 26
25ml round-bottomed flask adds compound 26A (200mg, 1.59mmol), compound 26B (424mg, 1.45mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (369mg, 1.74mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1) is for eluant, obtain white solid product 26 (194mg, productivity: 33.3%).1HNMR(400MHz,CDCl3) δ 7.96 (d, J=7.7Hz, 2H), 7.66 (t, J=7.4Hz, 1H), 7.54 (t, J=7.7Hz, 2H), 7.25 7.13 (m, 2H), 6.73 (d, J=7.7Hz, 1H), 3.86 (s, 2H), 3.42 (d, J=2.4Hz, 3H), 2.84 2.71 (m, 2H), 2.58 (dd, J=9.2,5.2Hz, 2H), 2.15 (s, 2H), 1.51 1.43 (m, 4H), 1.30 (d, J=4.5Hz, 2H), 0.96 0.78 (m, 2H)；MS(ESI)m/z[M]+: 401.17.
Embodiment 27
25ml round-bottomed flask adds compound 27A (400mg, 3mmol), compound 27B (796mg, 2.73mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (695mg, 3.28mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (4:1) is for eluant, obtain white solid product 27 (523mg, productivity: 46.8%).1HNMR(400MHz,CDCl3) δ 7.95 7.78 (m, 3H), 7.75 7.64 (m, 2H), 7.46 7.26 (m, 2H), 7.20 (dd, J=10.1,2.1Hz, 2H), 6.81 (dd, J=8.9,6.0Hz, 2H), 6.63 (dd, J=15.0,2.9Hz, 1H), 3.83 (s, 3H), 3.70 (s, 2H), 3.60 (s, 2H), 3.02 2.91 (m, 2H), 2.84 2.73 (m, 2H)；MS(ESI)m/z[M+H]+: 410.13.
Embodiment 28
50ml round-bottomed flask adds compound 28A (850mg, 4.4mmol), compound 28B (1168mg, 4.0mmol), ethyl acetate (10ml), adds sodium triacetoxy borohydride (1018mg, 4.8mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1), for eluant, obtains white solid (846mg), it is dissolved in dichloromethane, adding benzenesulfonic acid (314mg, 1.98mmol), heated and stirred lets cool precipitation solid after dissolving, filtration washing obtains white solid product 28 (518mg, productivity: 20.7%).1HNMR(400MHz,CDCl3) δ 7.95 7.78 (m, 3H), 7.75 7.62 (m, 2H), 6.97 (s, 1H), 6.88 (s, 1H), 6.81 (dd, J=8.9,6.0Hz, 2H), 6.63 (dd, J=15.0,2.9Hz, 1H), 3.83 (s, 3H), 3.75 (s, 6H), 3.70 (s, 2H), 3.60 (s, 2H), 3.01 2.92 (m, 2H), 2.84 2.75 (m, 2H)；MS(ESI)m/z[M]+: 469.49.
Embodiment 29
25ml round-bottomed flask adds compound 29A (309mg, 1.6mmol), compound 29B (400mg, 1.45mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (369mg, 1.74mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1) is for eluant, obtain white solid product 29 (216mg, productivity: 32.9%).1HNMR(400MHz,CDCl3)δ7.72–7.63(m,2H),7.41–7.29(m,4H),7.18–7.08(m,2H),6.97(s,1H),6.88(s,1H),5.90(s,1H),3.75(s,3H),3.73(s,3H),3.70(s,2H),3.62(s,2H),2.96(s,2H),2.79(s,2H),2.43(s,3H)；MS(ESI)m/z[M+H]+: 453.89.
Embodiment 30
Round-bottomed flask adds 30A (2.9g, 20mmol), add dichloromethane, 30B (4.2g is added after stirring and dissolving, 22mmol) with triethylamine (3.3ml, 24mmol), stir under room temperature and after 12h, TLC detection reacts completely, add water stirring 30min, be subsequently adding diluted ethyl acetate reactant liquor, organic facies is collected after separatory, aqueous phase extracts by ethyl acetate again, merges organic facies, saturated common salt water washing, anhydrous sodium sulfate dries, and finally concentration obtains crude product 30C (5.5g).
Take compound 30C (1.5g, 5mmol) it is placed in round-bottomed flask, add oxolane, raw material 30D (0.96g is added after dissolving, 5mmol), stir 10min, be subsequently adding STAB (1.27g, 6mmol), react under room temperature after 3h, TLC react completely and add saturated ammonium chloride solution cancellation reaction, extraction into ethyl acetate, merge organic facies, saturated common salt water washing, anhydrous sodium sulfate dries, through purification by silica gel column chromatography (separation condition) after concentration, obtain product 30 (1.8g, 75%).1HNMR(400MHz,CDCl3) δ 8.00 (d, J=8.3Hz, 1H), 7.79 (d, J=8.4Hz, 2H), 7.72 (d, J=7.7Hz, 1H), 7.56 (s, 1H), 7.36 7.31 (m, 1H), 7.26 7.20 (m, 3H), 6.62 (s, 1H), 6.50 (s, 1H), 3.85 (d, J=8.6Hz, 6H), 3.80 (s, 2H), 3.61 (d, J=13.2Hz, 2H), 2.82 (t, J=5.7Hz, 2H), 2.74 (t, J=5.6Hz, 2H), 2.36 (s, 3H), 2.07 (s, 1H)；MS(ESI)m/z[M+H]+: 476.59.
Embodiment 31
25ml round-bottomed flask adds compound 31A (309mg, 1.6mmol), compound 31B (400mg, 1.45mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (369mg, 1.74mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1) is for eluant, obtain white solid product 31 (176mg, productivity: 20.1%).1HNMR(400MHz,CDCl3) δ 7.85 (d, J=8.4Hz, 4H), 7.41 (d, J=8.3Hz, 2H), 7.35 (d, J=8.1Hz, 4H), 7.02 (d, J=8.3Hz, 2H), 6.64 (s, 1H), 6.54 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.71 (s, 2H), 3.58 (s, 2H), 2.86 (t, J=5.6Hz, 2H), 2.77 (t, J=5.7Hz, 2H), 2.49 (s, 6H)；MS(ESI)m/z[M+H]+: 607.07.
Embodiment 32
25ml round-bottomed flask adds compound 32A (322mg, 1.67mmol), compound 32B (300mg, 1.52mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (386mg, 1.83mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 32 (286mg, productivity: 50.1%).1HNMR(400MHz,CDCl3) δ 7.36 (ddd, J=8.5,6.9,2.9Hz, 4H), 7.12 (t, J=7.4Hz, 1H), 7.02 (ddd, J=8.5,7.7,1.4Hz, 4H), 6.63 (s, 1H), 6.52 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.69 (s, 2H), 3.59 (s, 2H), 2.86 (t, J=5.7Hz, 2H), 2.78 (t, J=5.6Hz, 2H)；MS(ESI)m/z[M+Na]+: 398.91.
Embodiment 33
25ml round-bottomed flask adds compound 33A (250mg, 1.30mmol), compound 33B (233mg, 1.68mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (300mg, 2.42mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 33 (196mg, productivity: 42.2%).1HNMR(400MHz,CDCl3) δ 7.39 7.30 (m, 3H), 7.19 (d, J=7.6Hz, 1H), 7.16 7.09 (m, 2H), 7.08 7.03 (m, 2H), 6.99 6.92 (m, 1H), 6.63 (s, 1H), 6.52 (s, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.70 (s, 2H), 3.60 (s, 2H), 2.85 (t, J=5.7Hz, 2H), 2.77 (t, J=5.6Hz, 2H)；MS(ESI)m/z[M+Na]+: 398.19.
Embodiment 34
25ml round-bottomed flask adds compound 34A (250mg, 1.30mmol), compound 34B (322mg, 1.68mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (300mg, 2.42mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with dichloromethane: methanol (10:1) is for eluant, obtain white solid product 34 (229mg, productivity: 39.2%).1HNMR(400MHz,CDCl3) δ 7.28 (dt, J=12.5,6.8Hz, 6H), 7.17 7.06 (m, 6H), 7.03 (t, J=7.3Hz, 2H), 6.64 (s, 1H), 6.56 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.68 (s, 2H), 3.63 (s, 2H), 2.87 (d, J=4.8Hz, 2H), 2.81 (d, J=5.2Hz, 2H)；MS(ESI)m/z[M+H]+: 451.09.
Embodiment 35
50ml round-bottomed flask adds compound 35A (1405mg, 7.28mmol), compound 35B (1000mg, 6.62mmol), ethyl acetate (5ml), adds sodium triacetoxy borohydride (1684mg, 7.94mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1), for eluant, obtains faint yellow color solid product 35C (916mg).
25ml round-bottomed flask adds compound 35C (400mg, 1.22mmol), two water stannum dichloride (1379mg; 6.1mmol), dehydrated alcohol (3ml), nitrogen protection; after stirring 30min in 70 DEG C; being cooled to room temperature, add in frozen water, the aqueous sodium carbonate of 5% adjusts pH value to 7-8; filter; filtrate is extracted with ethyl acetate, and anhydrous sodium sulfate dries, and is evaporated to obtain faint yellow solid 35D.
25ml round-bottomed flask adds compound 35D (250mg, 0.83mmol), compound 35E (173mg, 0.91mmol), triethylamine (168mg, 1.66mmol) with dichloromethane (5ml), at room temperature stir 4h, TLC and detect former 35D consumption completely.Through preparation TLC purification, (dichloromethane: methanol (15:1) is developing solvent) after concentration, obtain white solid product 35 (283mg, productivity: 75.4%).1HNMR(400MHz,CDCl3) δ 7.67 (d, J=8.3Hz, 2H), 7.30 (s, 1H), 7.28 (s, 1H), 7.25 (d, J=8.1Hz, 2H), 7.03 (d, J=8.4Hz, 2H), 6.61 (s, 1H), 6.48 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.63 (s, 2H), 3.53 (s, 2H), 2.82 (t, J=5.7Hz, 2H), 2.72 (t, J=5.8Hz, 2H), 2.40 (s, 3H)；MS(ESI)m/z[M+H]+: 453.17.
Embodiment 36
50mL round-bottomed flask adds compound 36A (400mg, 1.10mmol), pyridine (6mL), EDCI (316mg, 1.65mmol), 36B (178mg, 1.10mmol), reacts 8h in 90 DEG C of oil baths, evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merges organic facies, washing, anhydrous sodium sulfate dries, and separates purification through preparation TLC (dichloromethane: methanol 20:1) and obtain off-white color solid 36 (61mg, productivity 12.9%) after concentration.1HNMR(400MHz,CDCl3) δ 7.49 7.44 (m, 2H), 7.44 7.39 (m, 2H), 7.32 7.26 (m, 2H), 6.97 6.88 (m, 3H), 6.60 (s, 1H), 6.48 (s, 1H), 4.05 3.87 (m, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 3.71 (s, 2H), 3.69 3.58 (m, 2H), 3.55 (s, 2H), 3.35 3.05 (m, 4H), 2.83 (t, J=5.4Hz, 2H), 2.75 (t, J=5.6Hz, 2H)；MS(ESI)m/z[M+H]+: 472.20.
Embodiment 37
100mL round-bottomed flask adds 37A (500mg, 1.63mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (348 μ L, 4.08mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 37B, standby.100mL round-bottomed flask adds 37C (316mg, 1.63mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (272 μ L, 1.96mmol), be added dropwise over 37B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain white solid 37 (344mg, productivity 43.8%) after concentration.1HNMR(400MHz,CDCl3) δ 7.72 7.65 (m, 2H), 7.32 7.26 (m, 2H), 7.22 7.14 (m, 2H), 6.96 6.89 (m, 2H), 6.64 6.59 (m, 1H), 6.58 6.47 (m, 1H), 4.69 4.49 (m, 2H), 3.88 3.79 (m, 7H), 3.76 (s, 2H), 3.62 (t, J=5.9Hz, 1H), 2.80 2.58 (m, 2H), 2.43 (s, 3H)；MS(ESI)m/z[M+Na]+: 504.04.
Embodiment 38
100mL round-bottomed flask adds 38A (600mg, 1.96mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (417 μ L, 4.90mmol), N, N-dimethylformamide (1), stirring reaction 2h under room temperature, evaporated under reduced pressure solvent, obtain 38B, standby.100mL round-bottomed flask adds 38C (379mg, 1.96mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (327 μ L, 2.35mmol), be added dropwise over 38B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain light yellow solid 38 (360mg, productivity 38.1%) after concentration.1HNMR(400MHz,CDCl3) δ 7.77 7.70 (m, 2H), 7.36 7.26 (m, 3H), 7.24 7.13 (m, 2H), 7.03 6.92 (m, 1H), 6.60 (s, 1H), 6.58 6.51 (m, 1H), 4.68 4.47 (m, 2H), 3.89 3.82 (m, 6H), 3.80 (t, J=6.0Hz, 1H), 3.70 3.61 (m, 2H), 3.58 (t, J=5.9Hz, 1H), 2.79 2.58 (m, 2H), 2.49 2.41 (m, 3H)；MS(ESI)m/z[M+H]+: 482.15.
Embodiment 39
50mL round-bottomed flask adds 39A (100mg, 0.718mmol), dichloromethane (15mL), triethylamine (100 μ L, 0.718mmol), stirring and dissolving, adds 39B (200mg, 0.653mmol), stirring 5min, add sodium triacetoxy borohydride (166mg, 0.784mmol), under room temperature, stir 18h.Evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, washing, anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain white solid 39 (117mg, productivity 41.7%) after concentration.1HNMR(400MHz,CDCl3) δ 7.88 7.81 (m, 2H), 7.38 7.30 (m, 2H), 7.24 7.15 (m, 2H), 7.05 (d, J=5.1Hz, 1H), 6.77 (dd, J=7.1,2.5Hz, 1H), 6.68 (d, J=5.1Hz, 1H), 3.76 (s, 2H), 3.57 3.49 (m, 5H), 2.89 2.82 (m, 2H), 2.81 2.73 (m, 2H), 2.46 (s, 3H)；MS(ESI)m/z[M+Na]+: 452.11.
Embodiment 40
100mL round-bottomed flask adds 40A (500mg, 1.63mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (348 μ L, 4.08mmol), N, N-dimethylformamide (1), stirring reaction 2h under room temperature, evaporated under reduced pressure solvent, obtain 40B, standby.100mL round-bottomed flask adds 40C (316mg, 1.63mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (272 μ L, 1.96mmol), be added dropwise over 40B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain white solid 40 (327mg, productivity 41.6%) after concentration.1HNMR(400MHz,CDCl3) δ 7.74 7.62 (m, 2H), 7.33 7.26 (m, 2H), 7.24 7.14 (m, 2H), 7.07 6.95 (m, 1H), 6.90 6.70 (m, 1H), 6.62 (s, 1H), 6.60 6.50 (m, 1H), 4.73 4.45 (m, 2H), 4.00 3.71 (m, 9H), 3.59 (t, J=5.7Hz, 1H), 2.82 2.58 (m, 2H), 2.42 (s, 3H)；MS(ESI)m/z[M+Na]+: 504.09.
Embodiment 41
50mL round-bottomed flask adds 41A (150mg, 0.311mmol), anhydrous tetrahydro furan (6mL), stirring and dissolving is placed in ice bath, nitrogen protection, it is slowly added to lithium aluminium hydride (35mg, 0.934mmol), at room temperature stir 10min, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 41 (70mg is obtained through silica gel column chromatography (dichloromethane: methanol 50:1) purification after concentration, productivity 48.1%).1HNMR(400MHz,CDCl3)δ7.74–7.68(m,2H),7.32–7.28(m,2H),7.18–7.12(m,2H),6.93–6.87(m,2H),6.59(s,1H),6.52(s,1H),3.84(s,3H),3.83(s,3H),3.62(s,2H),2.90–2.80(m,4H),2.79–2.69(m,4H),2.44(s,3H)；MS(ESI)m/z[M+H]+: 468.11.
Embodiment 42
50mL round-bottomed flask adds 42A (100mg, 0.718mmol), dichloromethane (15mL), triethylamine (100 μ L, 0.718mmol), stirring and dissolving, adds 42A (200mg, 0.653mmol), stirring 5min, add sodium triacetoxy borohydride (166mg, 0.784mmol), under room temperature, stir 18h.Evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, washing, anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colorless oil 42 (124mg, productivity 44.2%) after concentration.1HNMR(400MHz,CDCl3) δ 7.77 7.72 (m, 2H), 7.25 7.18 (m, 3H), 7.12 (d, J=2.1Hz, 1H), 7.08 (d, J=5.1Hz, 1H), 6.81 (d, J=8.4Hz, 1H), 6.70 (d, J=5.1Hz, 1H), 3.60 (s, 3H), 3.59 (s, 2H), 3.48 (s, 2H), 2.85 (t, J=5.6Hz, 2H), 2.75 (t, J=5.6Hz, 2H), 2.41 (s, 3H)；MS(ESI)m/z[M+H]+: 430.05.
Embodiment 43
50mL round-bottomed flask adds 43A (100mg, 0.718mmol), dichloromethane (15mL), triethylamine (100 μ L, 0.718mmol), stirring and dissolving, adds 43B (191mg, 0.653mmol), stirring 5min, add sodium triacetoxy borohydride (166mg, 0.784mmol), under room temperature, stir 18h.Evaporated under reduced pressure solvent, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, washing, anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colorless oil 43 (125mg, productivity 46.2%) after concentration.1HNMR(400MHz,CDCl3) δ 7.92 7.86 (m, 2H), 7.67 7.61 (m, 1H), 7.54 7.48 (m, 2H), 7.13 7.07 (m, 2H), 6.93 (d, J=1.7Hz, 1H), 6.87 (dd, J=8.2,1.8Hz, 1H), 6.71 (d, J=5.1Hz, 1H), 3.65 (s, 2H), 3.55 (s, 2H), 3.53 (s, 3H), 2.88 (t, J=5.5Hz, 2H), 2.78 (t, J=5.6Hz, 2H)；MS(ESI)m/z[M+H]+: 416.15.
Embodiment 44
50mL round-bottomed flask adds 44A (150mg, 0.311mmol), anhydrous tetrahydro furan (6mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (35mg it is slowly added under nitrogen protection, 0.934mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 44 (81mg is obtained through silica gel column chromatography (dichloromethane: methanol 50:1) purification after concentration, productivity 55.7%).1HNMR(400MHz,CDCl3) δ 7.82 7.76 (m, 2H), 7.36 7.31 (m, 2H), 7.28 (dd, J=7.5,1.9Hz, 1H), 7.21 7.11 (m, 2H), 7.00 (dd, J=8.0,1.4Hz, 1H), 6.60 (s, 1H), 6.53 (s, 1H), 3.85 (s, 6H), 3.59 (s, 2H), 2.85 2.76 (m, 4H), 2.76 2.70 (m, 2H), 2.70 2.63 (m, 2H), 2.46 (s, 3H)；MS(ESI)m/z[M-H]-: 466.06.
Embodiment 45
50mL round-bottomed flask adds 45A (200mg, 0.415mmol), anhydrous tetrahydro furan (10mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (47mg it is slowly added under nitrogen protection, 1.24mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 45 (61mg is obtained through silica gel column chromatography (dichloromethane: methanol 50:1) purification after concentration, productivity 31.4%).1HNMR(400MHz,CDCl3) δ 7.72 7.67 (m, 2H), 7.31 7.26 (m, 2H), 7.19 (t, J=7.8Hz, 1H), 7.13 7.09 (m, 1H), 6.91 6.86 (m, 1H), 6.83 6.78 (m, 1H), 6.60 (s, 1H), 6.52 (s, 1H), 3.84 (s, 3H), 3.84 (s, 3H), 3.60 (s, 2H), 2.88 2.79 (m, 4H), 2.78 2.72 (m, 2H), 2.70 2.62 (m, 2H), 2.44 (s, 3H)；MS(ESI)m/z[M+H]+: 468.26.
Embodiment 46
25ml round-bottomed flask adds compound 46A (255mg, 1.32mmol), compound 46B (300mg, 1.19mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (306mg, 1.44mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with dichloromethane: methanol (20:1) is for eluant, obtain white solid product 46 (162mg, productivity: 31.7%).1HNMR(400MHz,CDCl3) δ 8.45 (s, 1H), 7.48 (d, J=7.2Hz, 2H), 7.38 (t, J=7.3Hz, 2H), 7.32 (d, J=7.2Hz, 1H), 7.29 7.21 (m, 3H), 6.96 (dd, J=8.8,2.4Hz, 1H), 6.61 (s, 1H), 6.49 (s, 1H), 5.11 (s, 2H), 3.91 (s, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 3.67 (s, 2H), 2.85 (s, 4H)；MS(ESI)m/z[M+H]+: 429.91.
Embodiment 47
25ml round-bottomed flask adds compound 47A (338mg, 1.75mmol), compound 47B (250mg, 1.59mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (405mg, 1.91mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain faint yellow solid product 47 (162mg, productivity: 31.7%).1HNMR(400MHz,CDCl3) δ 7.97 (d, J=1.8Hz, 1H), 7.52 7.42 (m, 1H), 6.63 (s, 1H), 6.51 (s, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.68 (s, 2H), 3.59 (s, 2H), 2.86 (t, J=5.7Hz, 2H), 2.77 (t, J=5.7Hz, 2H)；MS(ESI)m/z[M]+: 334.99.
Embodiment 48
25ml round-bottomed flask adds compound 48A (212mg, 1.1mmol), compound 48B (246mg, 1.0mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (254mg, 1.2mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain faint yellow solid product 48 (162mg, productivity: 31.7%).1HNMR(400MHz,CDCl3) δ 8.26 (dd, J=7.9,1.1Hz, 1H), 7.89 7.83 (m, 2H), 7.80 (d, J=7.6Hz, 1H), 7.61 7.57 (m, 1H), 7.48 (td, J=7.4,3.3Hz, 2H), 7.35 (t, J=7.8Hz, 2H), 6.55 (s, 1H), 6.42 (s, 1H), 3.95 (s, 2H), 3.85 (s, 3H), 3.82 (s, 3H), 3.42 (s, 2H), 2.57 (t, J=5.5Hz, 2H), 2.49 (t, J=5.7Hz, 2H)；MS(ESI)m/z[M+H]+: 424.06.
Embodiment 49
50ml round-bottomed flask adds compound 49A (1405mg, 7.28mmol), compound 49B (1000mg, 6.62mmol), ethyl acetate (5ml), adds sodium triacetoxy borohydride (1684mg, 7.94mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1), for eluant, obtains faint yellow color solid product 49C (683mg).
25ml round-bottomed flask adds compound 49C (400mg, 1.22mmol), two water stannum dichloride (1379mg; 6.1mmol); dehydrated alcohol (3ml), nitrogen protection, after stirring 30 minutes in 70 DEG C; it is cooled to room temperature; adding frozen water, the aqueous sodium carbonate of 5% adjusts pH value to 7-8, filters; filtrate is extracted with ethyl acetate, and anhydrous sodium sulfate is evaporated to obtain faint yellow solid 49D after drying.
25ml round-bottomed flask adds compound 49D (250mg, 0.83mmol), compound 49E (173mg, 0.91mmol), triethylamine (168mg, 1.66mmol) with dichloromethane (5ml), at room temperature stir 4h, TLC and detect raw material D consumption completely.Through preparation TLC purification, (dichloromethane: methanol (10:1) is developing solvent) after concentration, obtain white solid product 49 (218mg, productivity: 58.1%).1HNMR(400MHz,CDCl3) δ 7.67 (d, J=8.3Hz, 2H), 7.20 (dd, J=17.2,8.0Hz, 5H), 7.11 (d, J=8.1Hz, 2H), 7.03 (d, J=7.2Hz, 2H), 6.61 (s, 1H), 6.48 (s, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.60 (s, 2H), 3.49 (s, 2H), 2.79 (t, J=5.7Hz, 2H), 2.65 (t, J=5.8Hz, 2H), 2.19 (s, 3H)；MS(ESI)m/z[M+H]+: 453.00.
Embodiment 50
25ml round-bottomed flask adds compound 50A (245mg, 1.84mmol), compound 50B (500mg, 1.67mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (424mg, 2mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (8:1) is for eluant, obtain white solid product 50 (247mg, productivity: 35.5%).1HNMR(400MHz,CDCl3null)δ8.01(d,J=8.3Hz,1H),7.67(d,J=8.4Hz,2H),7.51(d,J=7.8Hz,1H),7.39(s,1H),7.38–7.31(m,1H),7.27–7.23(m,1H),7.19(d,J=8.1Hz,2H),7.01(dd,J=16.0,7.5Hz,2H),6.65(t,J=7.3Hz,1H),6.56(d,J=8.2Hz,1H),4.53(d,J=1.1Hz,2H),3.39–3.31(m,2H),2.83(t,J=6.3Hz,2H),2.36(s,3H),2.05–1.99(m,2H)；MS(ESI)m/z[M+Na]+: 439.08.
Embodiment 51
25ml round-bottomed flask adds compound 51A (318mg, 1.78mmol), compound 51B (494mg, 1.62mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (412mg, 1.99mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (2:1) is for eluant, obtain white solid product 51 (288mg, productivity: 37.9%).1HNMR(400MHz,CDCl3) δ 7.79 (d, J=8.3Hz, 2H), 7.32 (d, J=8.3Hz, 2H), 7.10 (d, J=8.1Hz, 1H), 6.97 (s, 1H), 6.89 (dd, J=8.2,1.4Hz, 1H), 6.68 (s, 1H), 6.49 (s, 1H), 3.85 (s, 3H), 3.62 (s, 2H), 3.58 (s, 3H), 3.53 (s, 2H), 2.80 (t, J=5.7Hz, 2H), 2.70 (t, J=5.8Hz, 2H), 2.46 (s, 3H)；MS(ESI)m/z[M+H]+: 470.25.
Embodiment 52
100mL round-bottomed flask adds 52A (600mg, 1.96mmol), dissolves with dichloromethane (10mL), add oxalyl chloride (417 μ L, 4.90mmol), DMF (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 52B.100mL round-bottomed flask adds 52C (273mg, 1.96mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (600 μ L, 4.31mmol), be added dropwise over 52B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and anhydrous sodium sulfate dries, and obtains colourless paste 52D (583mg, productivity 69.6%) through silica gel column chromatography (dichloromethane: methanol 100:1) after concentration.
50mL round-bottomed flask adds 52D (287mg, 0.671mmol), anhydrous tetrahydro furan (25mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (127mg it is slowly added under nitrogen protection, 3.36mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 52 (67mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 24.2%).1HNMR(400MHz,CDCl3) δ 7.81 7.76 (m, 2H), 7.36 7.31 (m, 2H), 7.29 7.24 (m, 1H), 7.22 7.12 (m, 2H), 7.08 (d, J=5.1Hz, 1H), 7.03 (dd, J=7.8,1.5Hz, 1H), 6.73 (d, J=5.1Hz, 1H), 3.59 3.55 (m, 2H), 2.92 2.85 (m, 2H), 2.84 2.73 (m, 4H), 2.73 2.66 (m, 2H), 2.46 (s, 3H)；MS(ESI)m/z[M+H]+: 414.12.
Embodiment 53
100mL round-bottomed flask adds 53A (435mg, 1.42mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (302 μ L, 3.55mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 53B, standby.100mL round-bottomed flask adds 53C (198mg, 1.42mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (435 μ L, 3.12mmol), be added dropwise over 53B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain light yellow paste 53D (437mg, productivity 72.0%) after concentration.
50mL round-bottomed flask adds 53D (300mg, 0.702mmol), anhydrous tetrahydro furan (15mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (107mg it is slowly added under nitrogen protection, 2.81mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 53 (51mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 17.6%).1HNMR(400MHz,CDCl3) δ 7.73 7.67 (m, 2H), 7.32 7.26 (m, 2H), 7.19 (t, J=7.8Hz, 1H), 7.14 7.06 (m, 2H), 6.89 6.85 (m, 1H), 6.84 6.79 (m, 1H), 6.73 (d, J=5.1Hz, 1H), 3.62 3.58 (m, 2H), 2.94 2.87 (m, 2H), 2.86 2.78 (m, 4H), 2.74 2.66 (m, 2H), 2.44 (s, 3H)；MS(ESI)m/z[M+H]+: 414.25.
Embodiment 54
100mL round-bottomed flask adds 54A (600mg, 1.96mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (417 μ L, 4.90mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 54B, standby.100mL round-bottomed flask adds 54C (273mg, 1.96mmol), dissolves with dichloromethane (10mL), stir under ice bath, add triethylamine (600 μ L, 4.31mmol), be added dropwise over 54B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste 54D (632mg, productivity 75.4%) after concentration.
50mL round-bottomed flask adds 54D (300mg, 0.702mmol), anhydrous tetrahydro furan (15mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (107mg it is slowly added under nitrogen protection, 2.81mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 54 (48mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 16.6%).1HNMR(400MHz,CDCl3) δ 7.74 7.68 (m, 2H), 7.33 7.28 (m, 2H), 7.17 7.11 (m, 2H), 7.08 (d, J=5.1Hz, 1H), 6.92 6.87 (m, 2H), 6.73 (d, J=5.1Hz, 1H), 3.64 3.60 (m, 2H), 2.94 2.81 (m, 6H), 2.80 2.72 (m, 2H), 2.45 (s, 3H)；MS(ESI)m/z[M+H]+: 414.29.
Embodiment 55
Adding 55A (1.0g, 8.1mmol) in 50ml round-bottomed flask, DMF (15ml) dissolves, and is subsequently adding piperazine (836mg, 9.7mmol) and K2CO3(1.68g, 12.2mmol), reacts 6h at 130 DEG C.To be cooled to room temperature, dilute, extraction into ethyl acetate, merge organic facies and dry with anhydrous sodium sulfate, through silica gel column chromatography (petroleum ether: ethyl acetate=5:1 after concentration；Dichloromethane: methanol=10:1) separate to obtain compound 55B (760mg, productivity 49.4%).
Being added in 50ml round-bottomed flask by 55B (760mg, 4.0mmol), add methylene chloride (15ml) dissolves, triethylamine (833 μ l are added under stirring, 6.0mmol) and TsCl (912mg, 4.8mmol), stir overnight under room temperature.Solvent evaporated, the residue obtained separates to obtain compound C (1.2g, productivity 87.1%), white solid through column chromatography (petroleum ether: ethyl acetate=5:1).
55C (344mg, 1.0mmol) is added in 50ml round-bottomed flask, adds ethyl acetate (15ml) and dissolve, then under agitation add 55D (290mg, 1.5mmol) and NaBH (OAc)3(424mg, 2mmol), reacts overnight under room temperature.Add saturated NaHCO3Cancellation is reacted, separatory, extraction into ethyl acetate aqueous phase, merges organic facies, separates to obtain compound 55 (138mg, productivity 26.4%), white solid through silica gel column chromatography (petroleum ether: ethyl acetate=1:1) after concentration.1HNMR(400MHz,CDCl3) δ 7.72 (d, J=8.3Hz, 2H), 7.51 7.49 (m, 1H), 7.39 (d, J=8.0Hz, 2H), 7.30 7.26 (m, 1H), 7.14 7.09 (m, 2H), 6.60 (s, 1H), 6.47 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.63 (s, 2H), 3.51 (s, 2H), 3.20 (brs, 4H), 3.11 3.08 (m, 4H), 2.78 (t, J=5.6Hz, 2H), 2.68 (t, J=5.7Hz, 2H), 2.49 (s, 3H)；MS(ESI)m/z[M+H]+: 522.41.
Embodiment 56
50ml round-bottomed flask adds 56A (1.0g, 8.1mmol), N, dinethylformamide (15ml) dissolves, and is subsequently adding piperazine (836mg, 9.7mmol) and potassium carbonate (1.68g, 12.2mmol), react 6h at 130 DEG C.To be cooled to room temperature, dilute, extraction into ethyl acetate, merge organic facies and dry with anhydrous sodium sulfate, through silica gel column chromatography (petroleum ether: ethyl acetate=5:1 after concentration；Dichloromethane: methanol=10:1) separate to obtain white solid product 56B (515mg, productivity 33.4%),.
Being added in 50ml round-bottomed flask by 56B (515mg, 2.71mmol), add methylene chloride (15ml) dissolves, triethylamine (565 μ l are added under stirring, 4.07mmol) and TsCl (616mg, 3.24mmol), stir overnight under room temperature.White solid product 56C (775mg, productivity 83.1%) is separated to obtain through column chromatography (petroleum ether: ethyl acetate=5:1) after concentration,.
56C (344mg, 1.0mmol) is added in 50ml round-bottomed flask, adds ethyl acetate (15ml) and dissolve, then under agitation add 56D (290mg, 1.5mmol) and NaBH (OAc)3(424mg, 2mmol), reacts overnight under room temperature.Add saturated NaHCO3Cancellation is reacted, separatory, extraction into ethyl acetate aqueous phase, merges organic facies, separates to obtain compound 56 (122mg, productivity 23.4%), white solid through silica gel column chromatography (petroleum ether: ethyl acetate=1:1) after concentration.1HNMR(400MHz,CDCl3) δ 7.70 (d, J=8.2Hz, 2H), 7.37 (d, J=8.0Hz, 2H), 7.30-7.28 (m, 2H), 6.86 (d, J=8.6Hz, 2H), 6.60 (s, 1H), 6.48 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.62 (s, 2H), 3.54 (s, 2H), 3.27 3.25 (m, 4H), 3.19-3.16 (m, 4H), 2.82 (t, J=5.6Hz, 2H), 2.73 (t, J=5.7Hz, 2H), 2.46 (s, 3H)；MS(ESI)m/z[M+H]+: 522.09.
Embodiment 57
50mL round-bottomed flask adds 57A (422mg, 0.852mmol), anhydrous tetrahydro furan (25mL), stirring and dissolving is placed in ice bath, lithium aluminium hydride (129mg it is slowly added under nitrogen protection, 3.41mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, light yellow paste 57 (62mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 15.1%).1HNMR(400MHz,CDCl3)δ7.73–7.67(m,2H),7.34–7.28(m,2H),7.14–7.07(m,2H),6.91–6.85(m,2H),6.59(s,1H),6.51(s,1H),3.84(s,3H),3.83(s,3H),3.67(s,2H),2.92–2.77(m,4H),2.69–2.55(m,4H),2.45(s,3H),2.02–1.89(m,2H)；MS(ESI)m/z[M+H]+: 482.26.
Embodiment 58
100mL round-bottomed flask adds 58A (500mg, 1.44mmol), dissolve with dichloromethane (15mL), add oxalyl chloride (307 μ L, 3.60mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 58B, standby.100mL round-bottomed flask adds 58C (220mg, 1.58mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (441 μ L, 3.17mmol), be added dropwise over 58B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste 58D (501mg, productivity 74.1%) after concentration.
50mL round-bottomed flask adds 58D (271mg; 0.577mmol); anhydrous tetrahydro furan (25mL); stirring and dissolving is placed in ice bath, nitrogen protection, is slowly added to lithium aluminium hydride (88mg; 2.31mmol); stir 10min under room temperature, 60 DEG C of oil baths are stirred 2h, is cooled to room temperature; methanol is dripped successively under stirring; saturated sodium bicarbonate aqueous solution cancellation, continues stirring 20min, sucking filtration; washing with alcohol; merging filtrate, obtains colourless paste 58 (66mg, productivity 25.1%) through preparation TLC (dichloromethane: methanol 100:1) purification after concentration.1HNMR(400MHz,CDCl3) δ 7.73 7.68 (m, 2H), 7.33 7.28 (m, 2H), 7.10 7.04 (m, 3H), 6.90 6.84 (m, 2H), 6.72 (d, J=5.1Hz, 1H), 3.57 (s, 2H), 2.90 (t, J=5.6Hz, 2H), 2.80 (t, J=5.7Hz, 2H), 2.61 2.49 (m, 4H), 2.45 (s, 3H), 1.67 1.55 (m, 4H), 1.41 1.30 (m, 2H)；MS(ESI)m/z[M+H]+: 456.21.
Embodiment 59
100mL round-bottomed flask adds 59A (600mg, 1.88mmol), dissolve with dichloromethane (15mL), add oxalyl chloride (399 μ L, 4.69mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 59B, standby.100mL round-bottomed flask adds 59C (288mg, 2.07mmol), dissolves with dichloromethane (20mL), stir under ice bath, add triethylamine (576 μ L, 4.14mmol), be added dropwise over 59B, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste 59D (679mg, productivity 81.8%) after concentration.
50mL round-bottomed flask adds 59D (333mg, 0.754mmol), anhydrous tetrahydro furan (20mL), stirring and dissolving is placed in ice bath, nitrogen protection, it is slowly added to lithium aluminium hydride (114mg, 3.02mmol), 10min is stirred under room temperature, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 59 (57mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 17.7%).1HNMR(400MHz,CDCl3) δ 7.74 7.68 (m, 2H), 7.33 7.28 (m, 2H), 7.13 7.05 (m, 3H), 6.91 6.85 (m, 2H), 6.72 (d, J=5.1Hz, 1H), 3.54 (s, 2H), 2.89 (t, J=5.6Hz, 2H), 2.77 (t, J=5.7Hz, 2H), 2.68 2.61 (m, 2H), 2.57 2.50 (m, 2H), 2.45 (s, 3H), 1.92 1.82 (m, 2H)；MS(ESI)m/z[M+H]+: 428.17.
Embodiment 60
100mL round-bottomed flask adds sodium hydroxide (4g), dissolves with water (50mL), be cooled to room temperature, add 60A (4.0g, 24.1mmol), stirring and dissolving, it is dividedly in some parts 60B (5.05g, 26.5mmol), stirred overnight at room temperature again.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitates out solid, sucking filtration, washing, collecting filter cake, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, filters insoluble matter, the filtrate obtained regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitate out solid, sucking filtration, washing, obtain white solid 60C (3.54g, productivity 45.9%) after drying.
100mL round-bottomed flask adds 60C (600mg, 1.88mmol), dissolve with dichloromethane (10mL), add oxalyl chloride (399 μ L, 4.69mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 60D, standby.100mL round-bottomed flask adds E39 (400mg, 2.07mmol), dissolves with dichloromethane (20mL), stir under ice bath, add triethylamine (288 μ L, 2.07mmol), be added dropwise over D39, drip and finish, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste 39 (635mg, productivity 68.2%) after concentration.1HNMR(400MHz,CDCl3) δ 7.73 7.65 (m, 2H), 7.34 7.27 (m, 2H), 7.17 7.10 (m, 2H), 6.91 6.84 (m, 2H), 6.65 6.50 (m, 2H), 4.54 (m, 2H), 3.89 3.82 (m, 6H), 3.80 (t, J=5.9Hz, 1H), 3.56 (t, J=5.9Hz, 1H), 3.02 2.92 (m, 2H), 2.77 2.69 (m, 2H), 2.69 2.62 (m, 2H), 2.44 (s, 3H)；MS(ESI)m/z[M+Na]+: 518.19.
Embodiment 61
100mL round-bottomed flask adds sodium hydroxide (1g), dissolves with water (20mL), be cooled to room temperature, add 61A (1.0g, 5.15mmol), stirring and dissolving, it is dividedly in some parts 61B (1.08g, 5.66mmol), stirred overnight at room temperature again.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitate out solid, sucking filtration, washing, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, filtering insoluble matter, the filtrate obtained regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitates out solid, sucking filtration, washing, obtains white solid 61C (1.04g, productivity 58.0%) after drying.
100mL round-bottomed flask adds 61C (500mg, 1.44mmol), dissolve with dichloromethane (15mL), add oxalyl chloride (307 μ L, 3.59mmol), N, dinethylformamide (1), stirring reaction 2h under room temperature, solvent evaporated, obtain 61D, standby.100mL round-bottomed flask adds 61E (306mg, 1.58mmol), dissolves with dichloromethane (15mL), stir under ice bath, add triethylamine (240 μ L, 1.73mmol), be added dropwise over 61D, react overnight under room temperature.Evaporated under reduced pressure solvent, is dissolved in water, extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and separates purification through silica gel column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste 61 (730mg, productivity 96.8%) after concentration.1HNMR(400MHz,CDCl3) δ 7.73 7.66 (m, 2H), 7.32 7.27 (m, 2H), 7.10 7.03 (m, 2H), 6.89 6.83 (m, 2H), 6.65 6.54 (m, 2H), 4.67 4.47 (m, 2H), 3.90 3.82 (m, 6H), 3.80 (t, J=5.9Hz, 1H), 3.62 (t, J=5.9Hz, 1H), 2.81 2.71 (m, 2H), 2.65 2.54 (m, 2H), 2.44 (s, 3H), 2.43 2.36 (m, 2H), 1.73 1.64 (m, 4H)；MS(ESI)m/z[M+Na]+,546.11。
Embodiment 62
50mL round-bottomed flask adds 62A (540mg, 1.03mmol), anhydrous tetrahydro furan (25mL), stirring and dissolving is placed in ice bath, nitrogen protection, it is slowly added to lithium aluminium hydride (157mg, 4.12mmol), at room temperature stir 10min, 60 DEG C of oil baths are stirred 2h, it is cooled to room temperature, methanol is dripped successively under stirring, saturated sodium bicarbonate aqueous solution cancellation, continue stirring 20min, sucking filtration, washing with alcohol, merging filtrate, colourless paste 62 (81mg is obtained through preparation TLC (dichloromethane: methanol 100:1) purification after concentration, productivity 15.4%).1HNMR(400MHz,CDCl3)δ7.72–7.68(m,2H),7.34–7.27(m,2H),7.10–7.03(m,2H),6.90–6.84(m,2H),6.59(s,1H),6.51(s,1H),3.84(s,3H),3.83(s,3H),3.66(s,2H),2.92–2.78(m,4H),2.63–2.50(m,4H),2.44(s,3H),1.73–1.55(m,4H),1.41–1.30(m,2H)；MS(ESI)m/z[M+H]+: 510.16.
Embodiment 63
25ml round-bottomed flask adds compound 63A (239mg, 1.79mmol), compound 63B (400mg, 1.63mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (416mg, 1.96mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 63 (257mg, productivity: 43.5%).1HNMR(400MHz,CDCl3) δ 8.30 (d, J=7.7Hz, 1H), 7.88 (d, J=7.5Hz, 2H), 7.81 (d, J=7.6Hz, 1H), 7.61 (t, J=7.2Hz, 1H), 7.55 7.42 (m, 2H), 7.35 (t, J=7.7Hz, 2H), 7.19 7.09 (m, 2H), 7.05 (d, J=6.6Hz, 1H), 6.94 (d, J=6.7Hz, 1H), 3.98 (s, 2H), 3.50 (s, 2H), 2.65 (t, J=5.7Hz, 2H), 2.52 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+: 364.14.
Embodiment 64
25ml round-bottomed flask adds compound 64A (313mg, 1.79mmol), compound 64B (400mg, 1.63mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (416mg, 1.96mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1) is for eluant, obtain white solid product 64 (201mg, productivity: 33.4%).1HNMR(400MHz,CDCl3) δ 8.29 (dd, J=7.9,1.3Hz, 1H), 7.90 7.81 (m, 2H), 7.76 (d, J=7.6Hz, 1H), 7.60 (td, J=7.5,1.3Hz, 1H), 7.56 7.44 (m, 2H), 7.34 (dd, J=10.7,4.9Hz, 2H), 7.07 (d, J=5.1Hz, 1H), 6.66 (d, J=5.1Hz, 1H), 4.00 (s, 2H), 3.44 (s, 2H), 2.63 2.49 (m, 4H)；MS(ESI)m/z[M+H]+: 370.07.
Embodiment 65
25ml round-bottomed flask adds compound 65A (200mg, 1.16mmol), compound 65B (260mg, 1.04mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (264mg, 1.24mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, then be extracted with ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with dichloromethane: methanol (15:1) is for eluant, obtain white solid product 65 (162mg, productivity: 38.7%).1HNMR(400MHz,CDCl3) δ 8.28 (dd, J=7.9,1.1Hz, 1H), 7.83 (dd, J=8.3,7.2Hz, 3H), 7.60 (dd, J=7.6,1.2Hz, 1H), 7.51 (t, J=7.2Hz, 1H), 7.45 (d, J=7.5Hz, 1H), 7.39 (t, J=7.4Hz, 1H), 7.30 7.24 (m, 3H), 7.19 7.08 (m, 2H), 4.05 (s, 2H), 3.56 (s, 2H), 2.66 (t, J=5.6Hz, 2H), 2.56 (t, J=5.3Hz, 2H)；MS(ESI)m/z[M-H]-: 401.11.
Embodiment 66
In 25ml round-bottomed flask, add 66A (126 μ l, 1mmol) and dichloromethane M, after stirring and dissolving, add 66B (270mg, 1mmol), it is subsequently adding STAB (254mg, 1.2mmol) to stir overnight, TLC detection reacts completely, washing, and water layer is extracted with ethyl acetate again, merge organic facies, washing with saturated common salt successively, anhydrous sodium sulfate dries, through purification by silica gel column chromatography after concentration, obtain product 66 (217mg, 60%).1HNMR(400MHz,CDCl3) δ 8.31 (d, J=7.5Hz, 1H), 7.94 (d, J=7.9Hz, 2H), 7.65 (t, J=7.4Hz, 1H), 7.53 (ddd, J=18.0,14.7,7.3Hz, 4H), 7.43 (d, J=7.5Hz, 1H), 6.96 (d, J=7.1Hz, 1H), 6.68 (t, J=7.7Hz, 1H), 6.53 (t, J=7.3Hz, 1H), 5.57 (d, J=8.2Hz, 1H), 4.64 (s, 2H), 3.37 3.26 (m, 2H), 2.82 (t, J=6.3Hz, 2H), 2.08 1.97 (m, 2H)；MS(ESI)m/z[M+H]+: 364.09.
Embodiment 67
In 25ml round-bottomed flask, add 67A (112 μ l, 1mmol) and dichloromethane, after stirring and dissolving, add 67B (270mg, 1mmol), it is subsequently adding STAB (254mg, 1.2mmol) to stir overnight, TLC detection reacts completely, washing, and water layer is extracted with ethyl acetate again, merge organic facies, washing with saturated common salt successively, anhydrous sodium sulfate dries, through purification by silica gel column chromatography after concentration, obtain product 67 (226mg, 65%).1HNMR(400MHz,CDCl3) δ 8.38 8.26 (m, 1H), 7.83 (dd, J=14.8,13.5Hz, 2H), 7.68 (d, J=7.6Hz, 1H), 7.63 7.42 (m, 5H), 7.07 (d, J=7.5Hz, 1H), 6.96 (t, J=7.6Hz, 1H), 6.68 (d, J=7.1Hz, 1H), 6.08 (d, J=7.8Hz, 1H), 4.53 (s, 2H), 3.17 (t, J=8.4Hz, 2H), 2.83 (dd, J=19.9,11.6Hz, 2H)；MS(ESI)m/z[M+H]+: 350.10.
Embodiment 68
In 25ml round-bottomed flask, add 68A (110 μ l, 1mmol) and dichloromethane, after stirring and dissolving, add 68B (270mg, 1mmol), it is subsequently adding STAB (254mg, 1.2mmol) to stir overnight, TLC detection reacts completely, washing, and water layer is extracted with ethyl acetate again, merge organic facies, saturated common salt is washed, and anhydrous sodium sulfate dries, through purification by silica gel column chromatography after concentration, obtain product 68 (171mg, 52%).1HNMR(400MHz,CDCl3) δ 8.21 (d, J=7.9Hz, 1H), 7.84 (d, J=8.0Hz, 2H), 7.66 (d, J=7.6Hz, 1H), 7.61 7.52 (m, 2H), 7.48 (t, J=7.6Hz, 3H), 3.79 (s, 2H), 2.77 2.14 (m, 11H)；MS(ESI)m/z[M+H]+: 331.16.
Embodiment 69
In 25ml round-bottomed flask, add 69A (159 μ l, 1mmol) and dichloromethane, after stirring and dissolving, add 69B (270mg, 1mmol), it is subsequently adding STAB (254mg, 1.2mmol) to stir overnight, TLC detection reacts completely, washing, water layer is extracted with ethyl acetate again, merges organic facies, saturated common salt water washing, anhydrous sodium sulfate dries, and obtains product 69 (217mg, 56%) through silica gel after concentration.1HNMR(400MHz,CDCl3) δ 8.22 (dd, J=7.9,1.0Hz, 1H), 7.90 7.80 (m, 2H), 7.67 (d, J=7.5Hz, 1H), 7.58 (dd, J=8.6,6.9Hz, 2H), 7.49 (dd, J=14.4,7.1Hz, 3H), 3.80 (s, 2H), 3.49 (s, 1H), 2.75 2.34 (m, 9H), 1.89 1.48 (m, 9H)；MS(ESI)m/z[M+H]+: 385.09.
Embodiment 70
By 70A (773mg, 4.0mmol) add in 100ml round-bottomed flask, and dissolve with dichloromethane (20ml), triethylamine (669 μ l it are initially charged under stirring, 4.8mmol), it is subsequently adding bromoacetate (442 μ l, 4.0mmol), under room temperature, reacts 30min.After reaction stops, separating (petroleum ether: ethyl acetate=2:1) through silica gel column chromatography after concentration and obtain compound 70B (800mg, productivity 71.6%).
Adding 70B (800mg, 2.86mmol) in 100ml round-bottomed flask, after methanol (20ml) dissolves, stirring is lower adds 30%NaOH solution (2ml), reacts 2h at 50 DEG C.After reaction stops, to be cooled after room temperature, it is slowly added to dense HCl and regulates PH to neutral, be evaporated to obtain white solid 70C crude product.
50mL round-bottomed flask adds the crude product of C (500mg), is dissolved in dichloromethane (10mL), is subsequently adding oxalyl chloride (213 μ l, 2.5mmol) and 1 DMF, reacts overnight under room temperature.Solvent evaporated and excessive oxalyl chloride, obtain 70D crude product.
Adding in 50ml round-bottomed flask by 70E (233mg, 1.0mmol), dichloromethane (10ml) dissolves, and is subsequently adding triethylamine (209 μ l, 1.5mmol).Crude product 70D dichloromethane (5ml) obtained in the previous step being dissolved, be slowly added dropwise, room temperature reaction is overnight.Compound 70 (70mg, productivity 15.0%) is separated to obtain through silica gel column chromatography (petroleum ether: ethyl acetate=2:1) after concentration.1HNMR(400MHz,CDCl3) δ 10.94 (s, 1H), 8.66 (d, J=8.4Hz, 1H), 8.12 (dd, J=8.0,1.6Hz, 1H), 7.77-7.75 (m, 2H), 7.63 7.59 (m, 1H), 7.53-7.49 (m, 1H), 7.32 7.25 (m, 3H), 6.71 (s, 1H), 6.58 (s, 1H), 3.89 (s, 3H), 3.89 (s, 3H), 3.80 (s, 2H), 3.33 (s, 2H), 3.10 (t, J=5.6Hz, 2H), 3.00 (t, J=5.8Hz, 2H)；MS(ESI)m/z[M+H]+: 467.12.
Embodiment 71
50mL round-bottomed flask adds compound 71A (250mg, 1.09mmol), sequentially add dichloromethane (8mL), triethylamine (152 μ L, 1.09mmol), compound 71B (323mg, 1.31mmol), 2h is stirred at room temperature, adds sodium triacetoxy borohydride (347mg, 1.64mmol), 30 DEG C of oil baths are stirred 24h.Reactant liquor is spin-dried for, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, water washing, anhydrous sodium sulfate dries, and the residue obtained after being spin-dried for separates purification through column chromatography (dichloromethane: methanol 200:1) and obtains compound as white solid 71 (67mg, productivity 14.6%).1HNMR (400MHz, CDCl3) δ 8.34 8.28 (m, 1H), 7.76 7.33 (m, 7H), 7.30 7.22 (m, 1H), 4.09 (s, 2H), 3.70 (s, 2H), 3.54 (t, J=5.4Hz, 2H), 2.69 (t, J=5.5Hz, 2H)；MS(ESI)m/z[M+H]+: 423.13.
Embodiment 72
50mL round-bottomed flask adds compound 72A (200mg, 0.956mmol), sequentially add dichloromethane (12mL), compound 72B (351mg, 1.15mmol), 2h is stirred at room temperature, adds sodium triacetoxy borohydride (304mg, 1.43mmol), stir overnight in 30 DEG C of oil baths.Reactant liquor is spin-dried for, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, water washing, anhydrous sodium sulfate dries, and the residue obtained after being spin-dried for separates purification through column chromatography (petroleum ether: ethyl acetate 10:1) and obtains compound as white solid 72 (71mg, productivity 14.9%).1HNMR(400MHz,CDCl3) δ 7.78 7.72 (m, 2H), 7.35 7.21 (m, 7H), 7.15 7.07 (m, 3H), 7.05 (d, J=1.8Hz, 1H), 7.03 6.97 (m, 1H), 6.76 (d, J=8.4Hz, 1H), 6.73 6.67 (m, 1H), 4.56 (s, 1H), 3.66 (d, J=13.5Hz, 1H), 3.58 (s, 3H), 3.13 (d, J=13.6Hz, 1H), 3.09 2.97 (m, 2H), 2.81 2.71 (m, 1H), 2.53 2.43 (m, 1H), 2.38 (s, 3H)；MS(ESI)m/z[M+H]+: 500.05.
Embodiment 73
50mL round-bottomed flask adds compound 73A (250mg, 1.09mmol), sequentially add dichloromethane (8mL), triethylamine (152 μ L, 1.09mmol), compound 73B (402mg, 1.31mmol), 2h is stirred at room temperature, adds sodium triacetoxy borohydride (347mg, 1.64mmol), 30 DEG C of oil baths are stirred 24h.Reactant liquor is spin-dried for, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, water washing, anhydrous sodium sulfate dries, and the residue obtained after being spin-dried for separates purification through column chromatography (dichloromethane: methanol 200:1) and obtains compound as white solid 73 (143mg, productivity 27.2%).1HNMR(400MHz,CDCl3) δ 7.78 7.70 (m, 2H), 7.32 7.27 (m, 2H), 7.22 7.18 (m, 1H), 7.16 (dd, J=8.4,1.8Hz, 1H), 6.81 (d, J=8.4Hz, 1H), 4.12 (t, J=5.4Hz, 2H), 3.83 (s, 2H), 3.68 (s, 2H), 3.55 (s, 3H), 2.92 (t, J=5.5Hz, 2H), 2.42 (s, 3H)；MS(ESI)m/z[M+Na]+: 505.05.
Embodiment 74
50mL round-bottomed flask adds compound 74A (250mg, 1.09mmol), sequentially add dichloromethane (8mL), triethylamine (152 μ L, 1.09mmol), compound 74B (402mg, 1.31mmol), 2h is stirred at room temperature, adds sodium triacetoxy borohydride (347mg, 1.64mmol), 30 DEG C of oil baths are stirred 24h.Reactant liquor is spin-dried for, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, water washing, anhydrous sodium sulfate dries, and the residue obtained after being spin-dried for separates purification through column chromatography (dichloromethane: methanol 200:1) and obtains compound as white solid 74 (103mg, productivity 19.6%).1HNMR(400MHz,CDCl3) δ 7.80 7.73 (m, 2H), 7.34 7.28 (m, 2H), 7.11 (d, J=8.0Hz, 1H), 6.88 6.81 (m, 2H), 4.13 (t, J=5.5Hz, 2H), 3.87 (s, 2H), 3.71 (s, 2H), 3.58 (s, 3H), 2.93 (t, J=5.5Hz, 2H), 2.45 (s, 3H)；MS(ESI)m/z[M+Na]+: 504.98.
Embodiment 75
50mL round-bottomed flask adds compound 75A (200mg, 0.956mmol), sequentially add dichloromethane (12mL), compound 75B (351mg, 1.15mmol), 2h is stirred at room temperature, adds sodium triacetoxy borohydride (304mg, 1.43mmol), stir overnight in 30 DEG C of oil baths.Reactant liquor is spin-dried for, residue adds saturated sodium bicarbonate aqueous solution, extraction into ethyl acetate, merge organic facies, water washing, anhydrous sodium sulfate dries, and the residue obtained after being spin-dried for separates purification through column chromatography (petroleum ether: ethyl acetate 10:1) and obtains compound as white solid 75 (185mg, productivity 38.7%).1HNMR(400MHz,CDCl3) δ 7.78 7.72 (m, 2H), 7.37 7.23 (m, 7H), 7.16 7.08 (m, 2H), 7.05 6.97 (m, 2H), 6.85 6.78 (m, 2H), 6.74 6.68 (m, 1H), 4.59 (s, 1H), 3.73 (d, J=13.8Hz, 1H), 3.53 (s, 3H), 3.21 (d, J=13.8Hz, 1H), 3.11 2.99 (m, 2H), 2.84 2.73 (m, 1H), 2.57 2.47 (m, 1H), 2.44 (s, 3H)；MS(ESI)m/z[M+H]+: 500.12.
Embodiment 76
Adding compound 76A (1000mg, 10.51mmol), dichloromethane (2ml), triethylamine (1592mg, 15.77mmol) in 50ml round-bottomed flask, stirring is lower adds compound 76B (2406mg, 12.62mmol).Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.Dilute with water after reaction system is concentrated, extraction into ethyl acetate, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (5:1), for eluant, obtains white solid product 76C.
25ml round-bottomed flask adds compound 76C (400mg, 1.61mmol), compound D (341mg, 1.77mmol), ethyl acetate (2ml), adds sodium triacetoxy borohydride (409mg, 1.93mmol) under stirring.Stirring overnight under room temperature, it is complete that TLC detects raw material reaction.React with saturated sodium bicarbonate aqueous solution cancellation, it is extracted with ethyl acetate again, merge organic layer, anhydrous sodium sulfate dries, through silica gel column chromatography after concentration, with petroleum ether: ethyl acetate (4:1), for eluant, obtains white solid product compound 76 (312mg, productivity: 45.5%).1HNMR(400MHz,CDCl3) δ 7.70 (d, J=8.2Hz, 2H), 7.37 (dd, J=3.2,1.8Hz, 1H), 6.88 (d, J=8.1Hz, 2H), 6.52 (s, 1H), 6.41 (s, 1H), 6.23 (dd, J=5.6,2.2Hz, 1H), 6.20 (d, J=1.5Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.76 (s, 2H), 3.37 (s, 2H), 2.57 (t, J=5.9Hz, 2H), 2.44 (t, J=5.8Hz, 2H), 2.20 (s, 3H)；MS(ESI)m/z[M]+: 426.92.
Embodiment 77
Experimental program and pertinent literature with reference to above example prepare compound 77, MS (ESI) m/z [M+H]+: 484.23.
Embodiment 78
Experimental program and pertinent literature with reference to above example prepare compound 78, MS (ESI) m/z [M+H]+: 484.11.
Embodiment 79
Experimental program and pertinent literature with reference to above example prepare compound 79, MS (ESI) m/z [M+H]+: 514.12.
Embodiment 80
Experimental program and pertinent literature with reference to above example prepare compound 80, MS (ESI) m/z [M+H]+: 514.13.
Embodiment 81
Experimental program and pertinent literature with reference to above example prepare compound 81, MS (ESI) m/z [M+H]+: 488.31.
Embodiment 82
Experimental program and pertinent literature with reference to above example prepare compound 82, MS (ESI) m/z [M+H]+: 454.01.
Embodiment 83
Experimental program and pertinent literature with reference to above example prepare compound 83, MS (ESI) m/z [M+H]+: 454.31.
Embodiment 84
Experimental program and pertinent literature with reference to above example prepare compound 84, MS (ESI) m/z [M+H]+: 484.10.
Embodiment 85
Experimental program and pertinent literature with reference to above example prepare compound 85, MS (ESI) m/z [M+H]+: 438.14.
Embodiment 86
Experimental program and pertinent literature with reference to above example prepare compound 86, MS (ESI) m/z [M+H]+: 452.08.
Embodiment 87
Experimental program and pertinent literature with reference to above example prepare compound 87, MS (ESI) m/z [M+H]+: 410.06.
Embodiment 88
Experimental program and pertinent literature with reference to above example prepare compound 88, MS (ESI) m/z [M+H]+: 452.14.
Embodiment 89
Experimental program and pertinent literature with reference to above example prepare compound 89, MS (ESI) m/z [M+H]+: 452.12.
Embodiment 90
Experimental program and pertinent literature with reference to above example prepare compound 90, MS (ESI) m/z [M+H]+: 438.16.
Embodiment 91
Experimental program and pertinent literature with reference to above example prepare compound 92, MS (ESI) m/z [M+H]+: 460.12.
Embodiment 92
Experimental program and pertinent literature with reference to above example prepare compound 92, MS (ESI) m/z [M+H]+: 406.22.
Embodiment 93
Experimental program and pertinent literature with reference to above example prepare compound 93, MS (ESI) m/z [M+H]+: 442.28.
Embodiment 94
Experimental program and pertinent literature with reference to above example prepare compound 94, MS (ESI) m/z [M+H]+: 395.25.
Embodiment 95
Experimental program and pertinent literature with reference to above example prepare compound 95, MS (ESI) m/z [M+H]+: 408.24.
Embodiment 96
Experimental program and pertinent literature with reference to above example prepare compound 96, MS (ESI) m/z [M+H]+: 440.20.
Embodiment 97
Experimental program and pertinent literature with reference to above example prepare compound 97, MS (ESI) m/z [M+H]+: 453.26.
Embodiment 98
Experimental program and pertinent literature with reference to above example prepare compound 98, MS (ESI) m/z [M+H]+: 438.16.
Embodiment 99
Experimental program and pertinent literature with reference to above example prepare compound 99, MS (ESI) m/z [M+H]+: 483.24.
Embodiment 100
Experimental program and pertinent literature with reference to above example prepare compound 100, MS (ESI) m/z [M+H]+: 454.27.
Embodiment 101
Experimental program and pertinent literature with reference to above example prepare compound 101, MS (ESI) m/z [M+H]+: 481.46.
Embodiment 102
Experimental program and pertinent literature with reference to above example prepare compound 102, MS (ESI) m/z [M+H]+: 412.24.
Embodiment 103
Experimental program and pertinent literature with reference to above example prepare compound 103, MS (ESI) m/z [M+H]+: 425.01.
Embodiment 104
Experimental program and pertinent literature with reference to above example prepare compound 104, MS (ESI) m/z [M+H]+: 414.28.
Embodiment 105
Experimental program and pertinent literature with reference to above example prepare compound 105, MS (ESI) m/z [M+H]+: 426.07.
Reference compound
Reference literature WO2010075469 prepares following compounds, and the spectroscopy data of following compound is consistent with document:
Reference literature WO2014150395 prepares following compounds, and the spectroscopy data of following compound is consistent with document:
Part of compounds biological test result of the present invention
One, the fluorescent quantitative PCR experiment detection medicine impact on hepatocyte PCSK9 gene expression dose
This experiment purpose is the reflection compound inhibitory action to PCSK9 gene expression, and compound is more strong to the inhibitory action of PCSK9 gene expression, it was shown that the potential fat-reducing effect of compound is more strong.
The detection medicine effect to HepG2 cell PCSK9mRNA:
By HepG2 cell (ATCC), by every hole 7 × 105The density of cells/well is seeded to 6 orifice plates, 37 DEG C, 5%CO2Overnight incubation.Next day, change liquid and add medicine to be measured and positive drug and process 24 hours.Extracting total serum IgE with Trizol reagent (Invitrogen), RNase-FreeDNase (Promega) processes.Every part of sample takes 1ugRNA, becomes cDNA as the template of real-time fluorescence quantitative PCR with M-MLV reverse transcriptase (Promega) reverse transcription.Use the PCSK9 quantification PCR primer through verifying, β-Actin quantification PCR primer as the primer of PCSK9 and reference gene β-Actin.The quantitative PCR reaction system of each sample is prepared with template, primer, PowerSYBRGreenPCRMasterMix (Invitrogen), quantitative PCR apparatus CFX96Real-TimePCRDetectionSystem (Bio-Rad) carries out real-time fluorescence quantitative PCR reaction by PCR instrument device description requirement, it is thus achieved that expression data.Δ Δ CT method is adopted to process expression data, with β-Actin for internal reference, the PCSK9 expression of blank is set as 1, try to achieve PCSK9 in all the other samples and, relative to the relative expression quantity (multiple relative to comparison) of comparison, assess the medicine impact on hepatocyte PCSK9 gene expression dose with this.
Experiments show that: the compounds of this invention, for instance: 1,3,5,6,7.8,9,13,14,16,17,18,19,20,21,22,27,28,29,30,32,33,36,37,38,39,40,41,42,43,44,45,48,51,52,53,55,56,57,58,59,60,61 etc., it is possible to PCSK9mRNA is expressed and plays strong inhibitory action.
Two, LDL uptake ratio test experiments:
The purpose of this experiment is the reflection compound effect to reducing LDL on a cellular level.LDL level crosses high energy atherogenicity.This experiment directly detects the ability of hepatocyte picked-up LDL from cellular level, can directly reflect the lipid-lowering effect of compound.
LDL uptake ratio cell model:
Surface of hepatocytes expresses ldl receptor, has the ability of picked-up LDL.Add the LDL (Dil-LDL) of fluorescent material Dil labelling in the medium, under fluorescence microscope, HepG2 hepatoma carcinoma cell be can be observed Dil-LDL is absorbed in cell.Medicine can make the amount of surface of hepatocytes ldl receptor increase thus strengthening the hepatocyte picked-up ability to LDL, therefore can be used on the fluorescence intensity that basis of microscopic observation arrives and evaluates sample hepatocyte absorbs the impact of LDL ability.
Cellar culture HepG2 cell (ATCC), is seeded to 96 orifice plates by the density of 2.5 × 104 cells in every hole, 37 DEG C, 5%CO2Overnight incubation.Next day, abandon supernatant, add sample and positive drug processes 20 hours.Abandoning supernatant, every hole adds the fresh culture of the epipolic Dil-LDL containing 2 μ g/ml (Invitrogen), at 37 DEG C, and 5%CO2Continue under condition to hatch 4 hours.Abandon supernatant, with PBS washed cell 2 times, change fresh culture, under fluorescence microscope (LeicaDMILLEDMicrosystems), observe the fluorescence intensity of every porocyte.To be not added with normal cell that sample and Dil-LDL process as negative control.Evaluate sample by the fluorescence intensity examined under a microscope and hepatocyte is absorbed the impact of LDL ability, and in addition classification, it is simple to compare.Stage division is as follows:
-represent compared with normal cell controls, without the fluorescence intensity increased；
+ represent compared with normal cell controls, the fluorescence intensity slightly increased；
++ represent compared with normal cell controls, the fluorescence intensity of medium increase；
+++ represent compared with normal cell controls, the fluorescence intensity strongly increased；
++++represent compared with normal cell controls, the fluorescence intensity strongly increased.
Test result indicate that: the compounds of this invention can strengthen the hepatocyte picked-up ability to LDL significantly.With compound C1 representative in document WO2010075469 and document WO2014150395, C2, C3, C4, C5 (structural formula sees above) compares, the hepatocyte that relatively low concentration the compounds of this invention processes is used to show the notable ability absorbing LDL, and the hepatocyte that reference compound processed at low concentration, to LDL almost without picked-up ability.Illustrate that the activity of the compounds of this invention increase hepatocyte picked-up LDL is significantly stronger than reference compound C1, C2, C3, C4, C5.
Three, the compound dual activation test experimental result to ERK and AMPK signal pathway:
With the compounds of this invention, HepG2 cell is processed, and detect the activation of ERK and AMPK.
Result shows: than undressed compared with control cells, dramatically increases at phosphorylated in the cell of compound treatment and activation ERK and AMPK.Including compound 3,7,9,16,17,18,19,21,23,28,29,32,33,36,37,38,39,40,41,42,43,44,45,48,51,52,53,54,55,56,57,59,60,61 etc..
Further, adopting the insulin resistant Mice model of obesity of High fat diet induction, the compounds of this invention has blood sugar lowering and reduces the effect of body weight, has and is obviously improved carbohydrate tolerance and insulin resistant, strengthens the feature of insulin sensitivity.
On the other hand, existing Research Literature shows: the activation of AMPK can suppress the downstream kinase of mTOR and Akt, and prompting AMPK/Akt/mTOR is probably the desirable target spot of oncotherapy.In existing Research Literature, cell experiment and zoopery are all pointed out, mTOR signal path can suppress the growth of tumor cell after suppressing, ERK and the AMPK of the compounds of this invention activation, can affecting the downstream kinase of mTOR and Akt further, prompting the compounds of this invention can be developed further into as antitumor drug.
Four, blood fat reducing experiment in SD rat model body:
Model is set up: customization fed with high SD rat, and normal group grows diet with common size Mus, gathers animal serum after 4 weeks, and Testing index changes.The rat of high lipid food induction is compared with normal rats, and in serum, LDL-C, TC equal size is increased significantly and has significant difference, it was demonstrated that high blood lipid model is successfully established.
Acute toxicity test: adopting single dose successive administration 7 days, test-compound, under the dosage of 500mg/kg, does not show apparent side effect.
Test group mediating recipe amount design: Normal group, hyperlipidemia model matched group, simvastatin group (8mg/kg), compound 17 groups (50mg/kg), compound 48 groups (50mg/kg).
Size of animal: often group 10.
Route of administration: oral administration gavage.
Administration frequency: once a day.
Administration time: 4 weeks.
Serum Indexes measures: after being administered 4 weeks, takes animal blood, is measured.
Measurement result induction and conclusion such as Fig. 2, Fig. 3, Fig. 4, Fig. 5.
The result of Fig. 2, Fig. 3, Fig. 4, Fig. 5 shows: the compounds of this invention 17, and compound 48 all can significantly reduce LDL-C and the TC of animal pattern.Fig. 4 and Fig. 5 shows, glutamate pyruvate transaminase and the glutamic oxaloacetic transaminase, GOT level of hyperlipidemia model group and simvastatin treated animal have significant rising, show abnormal liver function, but, the compounds of this invention, while showing notable internal Lipid-lowering activities, does not increase glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT level, compound 17, the glutamate pyruvate transaminase of compound 48 animal is consistent with normal diet treated animal with glutamic oxaloacetic transaminase, GOT level.Illustrate that the compounds of this invention is while blood fat reducing, liver is not caused damage by prompting, but simvastatin is while blood fat reducing, laboratory animal glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT level raise, illustrate that the animal pattern liver function taking simvastatin receives damage, also reveal that the obvious hepatotoxicity of statins.
Five, SD rat model nonalcoholic steatohepatitis experiment:
Zoologize explanation: what this experiment adopted zoologize uses animal for above-mentioned " in SD rat model body blood fat reducing experiment ", after animal serum index study completes, animal is put to death and dissects, take animal livers tissue, part formalin is fixed, partly-80 DEG C of freezen protective, carry out staining pathologic section (H&E dyeing, oil red-O dyeing) and check after being fixed for more than 48hr.Pay close attention to liver structure integrity, inflammatory cell infiltration and the fatty liver order of severity, and carry out (standards of grading: 0 grade: normal of marking；1 grade: < 20%；2 grades: 20-40%；3 grades: 40-60%；4 grades: 60-80%；5 grades: > 80%).Result is shown in following table.
Experimental animal group Empty bag degeneration Inflammation Fat Hyperemia under tunicle
Intact animal 0 0 0 0
High fat matched group 4 3 4 3
Simvastatin group 4 3 4 2
Compound 17 groups 2 1 2 1
Compound 48 groups 1 1 1 0
Result shows, hyperlipidemia model group is compared with normal group, in liver, the volume of adipose cell significantly increases, Macrovesicular steatosis occurs, fatty builds up the heavy damage organizational structure of liver, causes liver vacuolar degeneration, and with massive inflammatory cells infiltrated, above phenomenon shows, nonalcoholic steatohepatitis modeling success.After animal gavage takes part of compounds of the present invention, marking from vacuolar degeneration, compound 17, liver structure is all had certain protective effect by compound 48, and the hepar damnification caused due to adipose cell obtains certain reparation, reduces vacuolar degeneration degree；Compound 17, compound 48 can also significantly reduce inflammatory cell infiltration, reduces inflammation degree, and gathering and the adipose cell volume that can reduce fat increase, and liver fat degree alleviates.But, simvastatin treated animal liver anatomical, its liver structure integrity, inflammatory cell infiltration are consistent with hyperlipidemia model group with the fatty liver order of severity, and fatty liver symptom is not alleviated.The compounds of this invention 17, liver organization is all had certain protective effect by compound 48, and the compounds of this invention has the medical value for the treatment of fatty liver.
Above two experiments " in SD rat model body blood fat reducing experiment " and " experiment of SD rat model nonalcoholic steatohepatitis ", disclose the compounds of this invention and have a characteristic that
(1), the compounds of this invention show Lipid-lowering activities, without influence on liver normal function.In safe-dosaging limits, the compounds of this invention embodies the activity of internal blood fat reducing, does not cause the rising of rat transaminase level, and liver is not caused damage by prompting.But, simvastatin fat-reducing medicament, while showing Lipid-lowering activities, further such that the rising of animal transaminase level, illustrate that normal liver function receives damage, show obvious hepatotoxicity.The compounds of this invention blood fat reducing but do not affect the feature of liver function, in clinical practice, prompting the compounds of this invention has comparatively significant security advantages than statins.
(2), the compounds of this invention hyperlipidemia model Animal fat liver symptom is had potential therapeutical effect, and the lipid lowerers such as Statins do not have above curative effect.Can be seen that from " experiment of SD rat model nonalcoholic steatohepatitis ", the compounds of this invention reduces inflammation degree, gathering and the adipose cell volume that can reduce fat increase, liver fat degree alleviates, the hepar damnification that adipose cell causes obtains certain reparation, reduces vacuolar degeneration degree.But, simvastatin treated animal liver anatomical, its liver structure integrity, inflammatory cell infiltration are consistent with hyperlipidemia model group with the fatty liver order of severity, and fatty liver symptom is not alleviated.
Comprehensive above internal and Pharmacodynamics in vitro is tested, can be seen that, the compounds of this invention effect for reducing fat mechanism, it is different from existing listing fat-reducing medicament (such as: Statins, fibrates etc.), its excellent Lipid-lowering activities and its good security features, and the potential therapeutic value in fatty liver is treated, be expected to become vast cardiovascular patient and obtain the good fat-reducing medicament of new generation treating income.

Claims (13)

1. the compound of Formula V
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof；Wherein:
Annular atoms A or E is each independently selected from carbon atom or nitrogen-atoms；
A and E is connected with each other and is connected into 3～10 ring Y, meets valence bond theory during cyclization, and 3～10 described ring Y are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R1, R2, R3, R4, R5, R6Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
Z is-O-,-S-,-NH-,-CR5R6-,-C (O) O-,-C (O) NH-,-SO2O-,-SO2NH-, or Z is not for any atom (two groups namely, being connected with Z are connected either directly through chemical bond)；
Ring X is 3～10 rings, and 3～10 described ring X are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ", -OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R ' and R " independent is hydrogen or be substituted or the alkyl that is unsubstituted, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl,
At-NR ' R " ,-C (O) NR ' R " ,-OC (O) NR ' R " and ,-OS (O)nNR ' R " ,-OS (O)nNH (C=O) NR ' R " in, wherein NR ' R " can be 4 to 20 member heterocyclic ring containing nitrogen bases；
M=0,1,2；
N=1,2,3；
P=1,2,3；
Q=0,1,2,3,4,5,6；
R=0,1；
S=0,1,2.
2. general formula compound according to claim 1 (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VI),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
Annular atoms A or E is each independently selected from carbon or nitrogen-atoms；
A and E is connected with each other and is connected into 3～10 ring Y, meets valence bond theory during cyclization, and 3～10 described ring Y are selected from cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein,
Described cycloalkyl, heterocyclic radical, aryl, heteroaryl independently of one another by one or more selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced；
R9, R10, R11, R12, R13, R14Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R5, R6, R ', R ", Z, ring X, m, n, q, r are with claim 1.
3. general formula compound according to claim 1 (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R9, R10, R11, R12, R13, R14Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R15, R16, R17, R18It is hydrogen independently, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R5, R6, R ', R ", Z, annular atoms A, ring X, m, n, q, r are with claim 1.
4. general formula compound according to claim 2 (VII), wherein, R9, R10, R11, R12, R13, R14It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R15, R16, R17, R18It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
5. general formula compound according to claim 1 (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VIII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R19, R20, R21, R22, R23It is hydrogen independently, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
Annular atoms A and E, ring Y, R1, R2, R3, R4, R5, R6, R ', R ", Z, m, n, p, q, r, s is with claim 1.
6. general formula compound according to claim 4 (VIII), wherein, R19, R20, R21, R22, R23It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
7. general formula compound according to claim 1 (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (IX),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
R9, R10, R11, R12, R13, R14, R15, R16, R17, R18With claim 3；
R19, R20, R21, R22, R23With claim 5；
R5, R6, annular atoms A, q, r are with claim 1.
8. general formula compound according to claim 7 (IX), wherein: R15, R16, R17, R18, R19, R20, R21, R22, R23It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl；
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
9. the compound according to claim 1～8, this compound is selected from following compound, but is not limited to following compound range:
Or its medicinal acceptable salt.
10. preparing a logical compound shown in formula V, its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof described in claim 1, it comprises the following steps:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compound V by connecting.
11. a pharmaceutical composition, its compound comprising any one in claim 1 to 9 and pharmaceutically acceptable carrier.
12. any one compound is used for the purposes reducing in the medicine of the lipid levels of patients blood plasma and/or liver in preparation in claim 1 to 9.
13. any one compound is used for treating type ii diabetes in preparation in claim 1 to 9, hyperglycemia, obesity, insulin resistance, antitumor, and treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, the disease of fatty degeneration of liver and metabolism syndrome composition or the purposes in the medicine of the patient's condition.
CN201610009779.2A 2015-01-09 2016-01-08 Aromatic-ring azacyclo derivatives and application thereof Pending CN105777632A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510013164 2015-01-09
CN2015100131642 2015-01-09

Publications (1)

Publication Number Publication Date
CN105777632A true CN105777632A (en) 2016-07-20

Family

ID=56390063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610009779.2A Pending CN105777632A (en) 2015-01-09 2016-01-08 Aromatic-ring azacyclo derivatives and application thereof

Country Status (1)

Country Link
CN (1) CN105777632A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10208048B2 (en) 2015-04-28 2019-02-19 Janssen Sciences Ireland Uc RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11339165B2 (en) 2017-11-29 2022-05-24 Janssen Sciences Ireland Unlimited Company Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US11491157B2 (en) 2018-01-31 2022-11-08 Janssen Sciences Ireland Unlimited Company Co Cork, IE Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US11084826B2 (en) 2015-04-28 2021-08-10 Janssen Sciences Ireland Unlimited Company RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10611769B2 (en) 2015-04-28 2020-04-07 Janssen Sciences Ireland Unlimited Company RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10208048B2 (en) 2015-04-28 2019-02-19 Janssen Sciences Ireland Uc RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11339165B2 (en) 2017-11-29 2022-05-24 Janssen Sciences Ireland Unlimited Company Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
US11491157B2 (en) 2018-01-31 2022-11-08 Janssen Sciences Ireland Unlimited Company Co Cork, IE Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
US11352356B2 (en) 2018-03-13 2022-06-07 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors

Similar Documents

Publication Publication Date Title
CN105777632A (en) Aromatic-ring azacyclo derivatives and application thereof
CN105753814A (en) Substituted nitrogen heterocyclic derivative and application thereof
CN105753817A (en) Nitrogen-substituted heterocyclic derivatives and application thereof
CN105814067B (en) The prodrug of pyridine keto-amide as sodium channel modulators
CN109219604B (en) Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
JP5848761B2 (en) Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
DE60035779T2 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
CN104066431B (en) Pyrazine kinase inhibitors
CN106456795A (en) Targeted therapeutics
CN102485721A (en) Substituted 2,3-phthalazinone compounds and application thereof
CN102271682A (en) P2x3, receptor antagonists for treatment of pain
CN109970745A (en) Substituted pyrrolo-triazine class compound and its medical composition and its use
CN105777633A (en) Tetrahydroisoquinoline derivative and application thereof
MX2014015938A (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders.
CN105246887A (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
CN108349947B (en) Tetrahydroindazoles and pharmaceutical uses thereof
CA3161373A1 (en) Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras
RU2468015C2 (en) Polymorphic forms of deferasirox (icl670a)
CN104903293A (en) New anti-invasive compounds
CN104230912B (en) Quinoline, Its Preparation Method And Use
CN107207476A (en) Indoles and 7-azaindole derivatives and its for the purposes in neurodegenerative disorders
CN103360342B (en) 3-cyano-aniline alkylaryl bridged piperazine derivatives and preparing the application in medicine
CN103183682A (en) C-10 site carbamido substituted artemisinin derivative, preparation method and application
CN104926804B (en) One kind has compound, the preparation method and use of antitumor action
CN109096272A (en) A kind of indoles hydroxamic acid compound with anti-tumor activity and its application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160720